

Procedure Codes

2023 BayCarePlus v7 Effective 10/27/2023

NOTE: Yellow highlight denotes new procedure code(s) for 2023.	
DIAGNOSTIC RADIOLOGY	
MRA	
Magnetic resonance angiography, head; without contrast material(s)	70544
Magnetic resonance angiography, head; with contrast material(s)	70545
Magnetic resonance angiography, head; without contrast material(s) followed by contrast material(s) and futher sequences	70546
Magnetic resonance angiography, neck; without contrast material(s)	70547
Magnetic resonance angiography, neck; with contrast material(s)	70548
Magnetic resonance angiography, neck; without contrast material(s), followed by contrast material(s) and further sequences	70549
Magnetic resonance angiography, chest (excluding myocardium), with or without contrast material(s)	71555
Magnetic resonance angiography with contrast, chest (excluding myocardium)	C8909
Magnetic resonance angiography without contrast, chest (excluding myocardium)	C8910
Magnetic resonance angiography without contrast followed by with contrast, chest (excluding myocardium)	C8911
Magnetic resonance angiography, spinal canal and contents, with or without contrast material(s)	72159
Magnetic resonance angiography with contrast, spinal canal and contents	C8931
Magnetic resonance angiography without contrast, spinal canal and contents	C8932
Magnetic resonance angiography without contrast followed by with contrast, spinal canal and contents	C8933
Magnetic resonance angiography, pelvis, with or without contrast material(s)	72198
Magnetic resonance angiography with contrast, pelvis	C8918
Magnetic resonance angiography without contrast, pelvis	C8919
Magnetic resonance angiography without contrast followed by with contrast, pelvis	C8920
Magnetic resonance angiography, upper extremity, with or without contrast material(s)	73225
Magnetic resonance angiography with contrast, upper extremity	C8934
Magnetic resonance angiography without contrast, upper extremity	C8935
Magnetic resonance angiography without contrast followed by with contrast, upper extremity	C8936
Magnetic resonance angiography, lower extremity, with or without contrast material(s)	73725
Magnetic resonance angiography with contrast, lower extremity	C8912
Magnetic resonance angiography without contrast, lower extremity	C8913
Magnetic resonance angiography without contrast followed by with contrast, lower extremity	C8914
Magnetic resonance angiography, abdomen, with or without contrast material(s)	74185
Magnetic resonance angiography with contrast, abdomen	C8900
Magnetic resonance angiography without contrast, abdomen	C8901
Magnetic resonance angiography without contrast followed by with contrast, abdomen	C8902

MRI Magnetic resonance (eg, proton) imaging, temporomandibular joint(s)	70336
Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast material(s)	70540
Nagnetic resonance (eg, proton) imaging, orbit, face, and/or neck; with contrast material(s)	70542
Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast material(s), ollowed by contrast material(s) and further sequences	70543
Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material	70551
Agnetic resonance (eg, proton) imaging, brain (including brain stem); with contrast material	70552
agnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, ollowed by contrast material(s) and further sequences	70553
lagnetic resonance imaging, brain, functional MRI; including test selection and administration of epetitive body part movement and/or visual stimulation, not requiring physician or psychologist dministration	70554
lagnetic resonance imaging, brain, functional MRI; including test selection and administration of epetitive body part movement and/or visual stimulation, requiring physician or psychologist dministration of entire neurofunctional testing	70555
lagnetic resonance (eg, proton) imaging, chest (eg, for evaluation of hilar and mediastinal mphadenopathy); without contrast material(s)	71550
lagnetic resonance (eg, proton) imaging, chest (eg, for evaluation of hilar and mediastinal mphadenopathy); with contrast material(s)	71551
agnetic resonance (eg, proton) imaging, chest (eg, for evaluation of hilar and mediastinal mphadenopathy); without contrast material(s), followed by contrast material(s) and further equences	71552
agnetic resonance (eg, proton) imaging, spinal canal and contents, cervical; without contrast aterial	72141
agnetic resonance (eg, proton) imaging, spinal canal and contents, cervical; with contrast aterial(s)	72142
agnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, llowed by contrast material(s) and further sequences; cervical	72156
agnetic resonance (eg, proton) imaging, spinal canal and contents, thoracic without contrast aterial	72146
agnetic resonance (eg, proton) imaging, spinal canal and contents, thoracic with contrast aterial(s)	72147
agnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, llowed by contrast material(s) and further sequences; thoracic	72157
agnetic resonance (eg, proton) imaging, spinal canal and contents, lumbar; without contrast aterial	72148
agnetic resonance (eg, proton) imaging, spinal canal and contents, lumbar; with contrast aterial(s)	72149
agnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, llowed by contrast material(s) and further sequences; lumbar	72158
agnetic resonance (eg, proton) imaging, pelvis; without contrast material(s)	72195
agnetic resonance (eg, proton) imaging, pelvis; with contrast material(s) agnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by	72196 72197
ontrast material(s) and further sequences agnetic resonance (eg, proton) imaging, upper extremity, other than joint; without contrast	73218
aterial(s) agnetic resonance (eg, proton) imaging, upper extremity, other than joint; with contrast aterial(s)	73219
agnetic resonance (eg, proton) imaging, upper extremity, other than joint; without contrast atterial(s), followed by contrast material(s) and further sequences	73220
agnetic resonance (eg, proton) imaging, any joint of upper extremity; without contrast aterial(s)	73221
agnetic resonance (eg, proton) imaging, any joint of upper extremity; with contrast material(s)	73222
agnetic resonance (eg, proton) imaging, any joint of upper extremity; without contrast atterial(s), followed by contrast material(s) and further sequences	73223
agnetic resonance (eg, proton) imaging, lower extremity other than joint; without contrast naterial(s)	73718
lagnetic resonance (eg, proton) imaging, lower extremity other than joint; with contrast naterial(s)	73719

MRI (conf)	
Magnetic resonance (eg, proton) imaging, lower extremity other than joint; without contrast material(s), followed by contrast material(s) and further sequences	73720
Magnetic resonance (eg, proton) imaging, any joint of lower extremity; without contrast material	73721
Magnetic resonance (eg, proton) imaging, any joint of lower extremity; with contrast material(s)	73722
Magnetic resonance (eg, proton) imaging, any joint of lower extremity; without contrast material(s) and further sequences	73723
Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s)	74181
Magnetic resonance (eg, proton) imaging, abdomen; with contrast material(s)	74182
Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences	74183
Magnetic resonance (eg, proton) imaging, fetal, including placental and maternal pelvic imaging when performed; single or first gestation	74712
Cardiac magnetic resonance imaging for morphology and function without contrast material;	75557
Cardiac magnetic resonance imaging for morphology and function without contrast material; vith stress imaging	75559
Cardiac magnetic resonance imaging for morphology and function without contrast material(s), ollowed by contrast material(s) and further sequences;	75561
Cardiac magnetic resonance imaging for morphology and function without contrast material(s), ollowed by contrast material(s) and further sequences; with stress imaging	75563
Cardiac magnetic resonance imaging for morphology and function, quantification of segmental dysfunction; with strain imaging	C9762
Cardiac magnetic resonance imaging for morphology and function, quantification of segmental dysfunction; with stress imaging	C9763
Aagnetic resonance imaging, breast, without contrast material; unilateral	77046
Agnetic resonance imaging, breast, without and with contrast material(s), including computer- nided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; unilateral	77048
Magnetic resonance imaging with contrast, breast; unilateral	C8903
Magnetic resonance imaging without contrast followed by with contrast, breast; unilateral	C8905
Nagnetic resonance imaging, breast, without contrast material; bilateral	77047
Magnetic resonance imaging, breast, without and with contrast material(s), including computer- aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral	77049
Aagnetic resonance imaging with contrast, breast; bilateral	C8906
tagnetic resonance imaging without contrast followed by with contrast, breast; bilateral	C8908
tagnetic resonance (eg, proton) imaging, bone marrow blood supply	77084
Magnetic resonance imaging with inhaled hyperpolarized xenon-129 contrast agent, chest, acluding preparation and administration of agent Cardiac Nuclear Medicine	C9791
Ayocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional	78451
quantification, when performed); single study, at rest or stress (exercise or pharmacologic) Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or reinjection	78452
Ayocardial perfusion imaging, planar (including qualitative or quantitative wall motion, ejection raction by first pass or gated technique, additional quantification, when performed); single study, at rest or stress (exercise or pharmacologic)	78453
Ayocardial perfusion imaging, planar (including qualitative or quantitative wall motion, ejection raction by first pass or gated technique, additional quantification, when performed); multiple tudies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or reinjection	78454
Myocardial Imaging, infarct avid, planar; qualitative or quantitative	78466
Nyocardial Imaging with ejection fraction, first pass technique	78468
	78469
Myocardial Imaging, tomographic SPECT with or without quantification	
Myocardial Imaging, tomographic SPECT with or without quantification Cardiac Blood Pool Imaging, gated equilibrium; planar, single study Rest or Stress, wall motion tudy + ejection fraction, w/ or w/o quantitative processing Cardiac Blood Pooling Imaging, multiple studies, wall motion study plus ejection fraction, at rest or	78472

Cardiac Nuclear Medicine (cont)	
Cardiac Blood Pool Imaging, planar, first pass technique, single study, rest or stress, wall motion study + ejection fraction, w/ or w/o quantification	78481
Cardiac Blood Pool Imaging, multiple studies, rest and stress, wall motion study + ejection fraction, w/ or w/o quantification	78483
Cardiac Blood Pool Imaging, gated equilibrium, SPECT; planar, single study rest or stress, wall motion study + ejection fraction, w/ or w/o quantitative processing	78494
PET	
Myocardial imaging, positron emission tomography (PET), metabolic evaluation study (including ventricular wall motion(s) and/or ejection fraction(s), when performed, single study;	78459
Myocardial imaging, positron emission tomography (PET), metabolic evaluation study (including ventricular wall motion(s) and/or ejection fraction(s), when performed, single study; with concurrently acquired computed tomography transmission scan	78429
Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion(S) and/or ejection fraction(s), when performed; single study at rest or stress (exercise or pharmacologic)	78491
Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion(s) and/or ejection fraction(s), when performed; single study, at rest or stress (exercise or pharmacologic), with concurrently acquired computed tomography transmission scan	78430
Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion(S) and/or ejection fraction(s), when performed; multiple studies at rest or and stress (exercise or pharmacologic)	78492
Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion(s) and/or ejection fraction(s), when performed; multiple studies, at rest and stress (exercise or pharmacologic), with concurrently acquired computed tomography transmission scan	78431
Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion(s) and/or ejection fraction(s), when performed), dual radiotracer (eg, myocardial viability);	78432
Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion(s) and/or ejection fraction(s), when performed), dual radiotracer (eg, myocardial viability); with concurrently acquired computed tomography transmission scan	78433
Brain imaging, positron emission tomography (PET); metabolic evaluation	78608
Brain imaging, positron emission tomography (PET); perfusion evaluation	78609
Positron emission tomography (PET) imaging; limited area (eg, chest, head/neck)	78811
Positron emission tomography (PET) imaging; skull base to mid-thigh	78812
Positron emission tomography (PET) imaging; whole body	78813
Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; limited area (eg, chest, head/neck)	78814
Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh	78815
Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body	78816
PET imaging whole body; melanoma for noncovered indications	G0219
PET imaging, any site, not otherwise specified	G0235
PET imaging, full and partial-ring PET scanners only, for initial diagnosis of breast cancer and/or surgical planning for breast cancer (e.g., initial staging of axillary lymph nodes)	G0252
RADIATION THERAPY	
2D3D Rediction treatment delivery superficial and /or ortho voltage, per day	77.40.1
Radiation treatment delivery, superficial and/or ortho voltage, per day Radiation treatment delivery, >1 MeV; simple	77401 77402
Radiation treatment delivery, >1 MeV; simple Radiation treatment delivery, >1 MeV; intermediate	77402
Radiation treatment delivery, >1 MeV; complex	77412
Radiation treatment delivery, 51 MeV, complex Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: up to 5MeV	G6003
Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 6-10MeV	G6004

cels or no blocks: 11-19MeV didefion freatment delivery, single freatment area, single port or parallel opposed ports, simple acits or no blocks: 20MeV or greater didefion freatment delivery, 2 separate freatment areas, 3 or more ports on a single freatment ea, use of multiple blocks: up to 5MeV didefion freatment delivery, 2 separate freatment areas, 3 or more ports on a single freatment ea, use of multiple blocks: 4-10MeV didefion freatment delivery, 2 separate freatment areas, 3 or more ports on a single freatment ea, use of multiple blocks: 4-10MeV didefion freatment delivery, 2 separate freatment areas, 3 or more ports on a single freatment ea, use of multiple blocks: 11-19MeV didefion freatment delivery, 2 separate freatment areas, or more ports on a single freatment ea, use of multiple blocks: 20MeV or greater didefion freatment delivery, 3 or more separate freatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; us to 5MeV didefion freatment delivery, 3 or more separate freatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; 11-19MeV didefion freatment delivery, 3 or more separate freatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; 11-19MeV didefion freatment delivery, 3 or more separate freatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; 11-19MeV trapperative rodiotion treatment delivery, electrons single freatment session 7742 trapperative rodiotion treatment delivery, electrons single freatment session 7742 trapperative rodiotion treatment delivery, electrons single freatment session 7742 trapperative rodiotion source application; imple area of the single prodiction source application; imple area of the single prodiction source application; imple area of the single prodiction source application; complex incovitary radiotion source application; complex incovitary rodiotion source application; comple	2D3D (cont)	
cocks or no blocks: 11-19MeV acidation freatment delivery, single treatment area, single port or parallel apposed ports, simple acidation freatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment acidation freatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment acidation freatment delivery, 2 separate freatment areas, 3 or more ports on a single treatment acidation freatment delivery, 2 separate freatment areas, 3 or more ports on a single treatment acidation freatment delivery, 2 separate freatment areas, 3 or more ports on a single treatment acidation freatment delivery, 2 separate freatment areas, 3 or more ports on a single treatment acidation freatment delivery, 2 separate freatment areas, custom blocking, tangential acidation freatment delivery, 3 or more separate freatment areas, custom blocking, tangential aris, wedges, rotational beam, compensators, electron beam; 9 to 5 MeV acidation freatment delivery, 3 or more separate treatment areas, custom blocking, tangential aris, wedges, rotational beam, compensators, electron beam; 11-19MeV acidation freatment delivery, 3 or more separate treatment areas, custom blocking, tangential aris, wedges, rotational beam, compensators, electron beam; 20MeV or greater schylkerapy trapparative radiation freatment delivery, 2 more separate treatment areas, custom blocking, tangential aris, wedges, rotational beam, compensators, electron beam; 20MeV or greater schylkerapy trapparative radiation freatment delivery, x-ray, single treatment session 77424 trapparative radiation freatment delivery, selectron, single treatment session 77750 tracovitory radiation source application; intermediate tracovitary radiation source application; complex, i	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple	G6005
ocks or no blocks: 20MeV or greater diadiofin froatment delivery, 25 eparcel treatment areas, 3 or more ports on a single treatment ea, use of multiple blocks: up to 5MeV diadiofin froatment delivery, 25 eparcel treatment areas, 3 or more ports on a single treatment ea, use of multiple blocks: 4-10MeV diadiofin froatment delivery, 25 eparcel treatment areas, 3 or more ports on a single treatment ea, use of multiple blocks: 11-19MeV diadiofin froatment delivery, 25 eparcel treatment areas, 3 or more ports on a single treatment ea, use of multiple blocks: 20MeV or greater diadiofin treatment delivery, 3 or more separate treatment areas, custom blocking, tangential six, wedges, rotolational boarn, compensators, electron beam; up to 5MeV diadiofin treatment delivery, 3 or more separate treatment areas, custom blocking, tangential six, wedges, rotolational beam, compensators, electron beam; 11-19MeV diadiofin freatment delivery, 3 or more separate freatment areas, custom blocking, tangential six, wedges, rototanoal beam, compensators, electron beam; 11-19MeV diadiofin freatment delivery, 3 or more separate freatment areas, custom blocking, tangential six, wedges, rototanoal beam, compensators, electron beam; 11-19MeV diadiofin freatment delivery, 3 or more separate freatment areas, custom blocking, tangential six, wedges, rototanoal beam, compensators, electron beam; 20MeV or greater activity in a separate freatment delivery, x-ray, single treatment areas, custom blocking, tangential six, wedges, rotational beam, compensators, electron beam; 20MeV or greater activity in a separate freatment delivery, x-ray, single treatment session stantial propertive radiation treatment delivery, x-ray, single treatment session rotation activity radiation of radialements solution (includes 3 months follow-up care) rotation or institution of radialements solution (includes 3 months follow-up care) rotation or institution of radialements solution (includes 3 months follow-up care) rotation or institution of radialements soluti		
addition treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment eau, use of multiple blocks: up to 5 MeV addition treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment eau, use of multiple blocks: 610MeV addition treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment eau, use of multiple blocks: 1119MeV addition treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment eau, use of multiple blocks: 20MeV or greater diadition treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment eau, use of multiple blocks: 20MeV or greater diadition treatment delivery, 3 or more separate treatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; up to 5 MeV addition treatment delivery, 3 or more separate treatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; 11-19MeV addition treatment delivery, 3 or more separate treatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; 11-19MeV addition treatment delivery, 3 or more separate treatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; 20MeV or greater schylherapy trapperative radiation treatment delivery, xray, single treatment session 77424 trapperative radiation freatment delivery, xray, single treatment session 77425 trapperative radiation freatment delivery, xray, single treatment session 77426 trapperative radiation for addition finatment delivery, electrons, single treatment session 77427 trapperative radiation source application; finate finate file and properative radiation for addition file file and properative radiation for addition file file and file file file file file file file file		G6006
ea, use of multiple blocks: up to SMeV addiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment ea, use of multiple blocks: 4-10MeV addiation freatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment ea, use of multiple blocks: 11-19MeV addiation freatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment ea, use of multiple blocks: 20MeV or greater addiation freatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment ea, use of multiple blocks: 20MeV or greater addiation freatment delivery, 3 or more separate treatment areas, custom blocking, tangential stis, wedges, rotational beam, compensators, electron beam; up to SMeV addiation freatment delivery, 3 or more separate freatment areas, custom blocking, tangential stis, wedges, rotational beam, compensators, electron beam; 20MeV or greater diation freatment delivery, 3 or more separate freatment areas, custom blocking, tangential stis, wedges, rotational beam, compensators, electron beam; 11-19MeV diation freatment delivery, 3 or more separate freatment areas, custom blocking, tangential stis, wedges, rotational beam, compensators, electron beam; 20MeV or greater delivity rediation freatment delivery, x-ray, single treatment session stis, wedges, rotational beam, compensators, electron beam; 20MeV or greater delivity rediation freatment delivery, x-ray, single treatment session strain treatment delivery, and treatment delivery, electrons, single treatment session strain treatment delivery, and treatment delivery, electrons, single treatment session strain treatment delivery and treatment delivery, electrons, single treatment session strain treatment delivery and treatment delivery, electrons, single treatment session strain treatment delivery and treatment delivery process		
addition freatment delivery, 2 separate freatment areas, 3 or more ports on a single freatment equ. seo of multiple blocks: 6-10MeV addition freatment delivery, 2 separate freatment areas, 3 or more ports on a single freatment equ. seo from this ple blocks: 1-19MeV addition freatment delivery, 2 separate freatment areas, 3 or more ports on a single freatment equ. seo of multiple blocks: 20MeV or greater didition freatment delivery, 3 or more separate freatment areas, custom blocking, tangential aris, wedges, rotational beam, compensators, electron beam; up to 5MeV addition freatment delivery, 3 or more separate freatment areas, custom blocking, tangential aris, wedges, rotational beam, compensators, electron beam; 20MeV or greater delivery, 3 or more separate freatment areas, custom blocking, tangential aris, wedges, rotational beam, compensators, electron beam; 11-19MeV addition freatment delivery, 3 or more separate freatment areas, custom blocking, tangential aris, wedges, rotational beam, compensators, electron beam; 11-19MeV addition freatment delivery, 3 or more separate freatment areas, custom blocking, tangential aris, wedges, rotational beam, compensators, electron beam; 20MeV or greater schylherapy traperative radiation freatment delivery, xray, single treatment session 77424 traperative radiation source application; simple reatment session 77425 traperative radiation source application; simple reatment session 77762 tracovitary radiation source application; simple reatment session 77762 tracovitary radiation source application; simple reatment session 77763 77764 77767 77767 77767 77776 77776 77777 77770 77780		G6007
ea, use of multiple blocks: 6-10MeV addiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment ea, use of multiple blocks: 11-19MeV addiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment ea, use of multiple blocks: 20MeV or greater addiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential risk, wedges, rotational beam, compensators, electron beam; up to 5MeV addiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential risk, wedges, rotational beam, compensators, electron beam; 6-10MeV addiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential risk, wedges, rotational beam, compensators, electron beam; 20MeV or greater activitatory addiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential risk, wedges, rotational beam, compensators, electron beam; 20MeV or greater activitatory addiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential risk, wedges, rotational beam, compensators, electron beam; 20MeV or greater activitatory activitatory tangental readiation activity, and activity, electrons, single treatment session 77424 tacquerity readiation freatment delivery, xray, single treatment session 77425 tacquerity readiation freatment delivery, xray, single treatment session 77426 tracquerity readiation source application; intermediate 77761 tracquerity readiation source application; complex 77762 tracquerity readiation source application; complex 77763 more afterloading high dose rate radionuclide six surface brachytherapy, includes basic 77676 similarly, when performed; lesion diameter up to 2.0 cm and 2 or more channels, or multiple 77768 timete afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, 77770 tudes basic dosimetry, when performed; 2 channels 77789 the dose rate electronic brachytherapy, sikin surface applicat		
addition treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment eau, use of multiple blocks: 11-19MeV addition treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment eau, use of multiple blocks: 20MeV or greater contained and treatment delivery, 3 or more separate treatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; up to 5MeV addition treatment delivery, 3 or more separate treatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; 0-10MeV addition treatment delivery, 3 or more separate treatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; 11-19MeV addition treatment delivery, 3 or more separate treatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; 20MeV or greater **Celaylikactay** **Tataget and the separate area and the separate and the separate area and the separate and		G6008
ea, use of multiple blocks: 11-19MeV addition treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment ea, use of multiple blocks: 20MeV or greater addition freatment delivery, 3 or more separate treatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; up to SMeV addition freatment delivery, 3 or more separate freatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; up to SMeV addition freatment delivery, 3 or more separate freatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; 11-19MeV addition freatment delivery, 3 or more separate freatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; 11-19MeV argester activities and the separate freatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; 11-19MeV argester activities and the separate freatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; 20MeV argester activities and the separate freatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; 20MeV argester activities and the separate freatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; 20MeV argester activities and the separate freatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; 20MeV argester activities and the separate freatment areas, custom blocking, tangential arts, wedges, rotational blocking, tangential arts, wedges, rotational areas, custom blocking, tangential arts, wedges, rotational areas, custom blocking, tangential arts, wedges, rotational areas, custom blocking, tangential arts, areas, and the separate process of the separate freatment areas, custom blocking, tangential arts, wedges, and the separate process of the separate freatm		
addition freatment delivery, 2 separate freatment areas, 3 or more ports on a single treatment eq. use of multiple blocks; 20MeV or greater addition freatment delivery, 3 or more separate treatment areas, custom blocking, tangential atts, wedges, rotational beam, compensators, electron beam; up to 5MeV and addition freatment delivery, 3 or more separate treatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; 1-10MeV and addition freatment delivery, 3 or more separate treatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; 11-19MeV and addition freatment delivery, 3 or more separate treatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; 20MeV or greater addition freatment delivery, 3 or more separate treatment areas, custom blocking, tangential arts, wedges, rotational beam, compensators, electron beam; 20MeV or greater activities and additional real ment delivery, array, single freatment session 77425 activities and additional real ment delivery, electrons, single freatment session 77426 activities and additional freatment delivery, electrons, single freatment session 77427 activities and additional freatment delivery, electrons, single freatment session 77428 77497 activities and additional freatment delivery, electrons, single freatment session 77409 774		G6009
ea, use of multiple blocks: 20MeV or greater addition treatment delivery, 3 or more separate treatment areas, custom blocking, tangential offs, wedges, rotational beam, compensators, electron beam; up to 5MeV addition freatment delivery, 3 or more separate treatment areas, custom blocking, tangential offs, wedges, rotational beam, compensators, electron beam; up to 5MeV addition treatment delivery, 3 or more separate treatment areas, custom blocking, tangential offs, wedges, rotational beam, compensators, electron beam; 11-19MeV addition treatment delivery, 3 or more separate treatment areas, custom blocking, tangential offs, wedges, rotational beam, compensators, electron beam; 11-19MeV or greater **CellyNiterary** **CellyNiterary** **CellyNiterary** **Compensators of the compensators of th		
addation freatment delivery, 3 or more separate freatment areas, custom blocking, tangential aris, wedges, rotational beam, compensators, electron beam; up to 8MeV didation freatment delivery, 3 or more separate freatment areas, custom blocking, tangential aris, wedges, rotational beam, compensators, electron beam; e1 DMeV didation freatment delivery, 3 or more separate freatment areas, custom blocking, tangential aris, wedges, rotational beam, compensators, electron beam; 11-19MeV didation freatment delivery, 3 or more separate treatment areas, custom blocking, tangential aris, wedges, rotational beam, compensators, electron beam; 20MeV or greater didation freatment delivery, 3 or more separate treatment areas, custom blocking, tangential aris, wedges, rotational beam, compensators, electron beam; 20MeV or greater addition freatment delivery, 3 or more separate treatment areas, custom blocking, tangential aris, wedges, rotational beam, compensators, electron beam; 20MeV or greater activities arise		G6010
additation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential orts, wedges, rotational beam, compensators, electron beam; 6-10MeV additation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential orts, wedges, rotational beam, compensators, electron beam; 6-10MeV additation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential orts, wedges, rotational beam, compensators, electron beam; 11-17MeV additation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential orts, wedges, rotational beam, compensators, electron beam; 20MeV or greater addition treatment delivery, areas, single treatment session areas, custom blocking, tangential orts, wedges, rotational beam, compensators, electron beam; 20MeV or greater and continuous delivery and continuous delivery and continuous delivery and continuous delivery areas, single treatment session areas, custom blocking, tangential orts, wedges, rotational beam, compensators, electron beam; 20MeV or greater and continuous delivery and continu		
addition treatment delivery, 3 or more separate treatment areas, custom blocking, tangential offs, wedges, rotational beam, compensators, electron beam; 6-10MeV addition treatment delivery, 3 or more separate treatment areas, custom blocking, tangential offs, wedges, rotational beam, compensators, electron beam; 11-19MeV addition treatment delivery, 3 or more separate treatment areas, custom blocking, tangential orfs, wedges, rotational beam, compensators, electron beam; 20MeV or greater 66014 activities of the separate treatment areas, custom blocking, tangential orfs, wedges, rotational beam, compensators, electron beam; 20MeV or greater 77424 77425 77426 77426 77427 77426 77427 77427 77427 77426 77426 77427 77427 77427 77427 77427 77427 7743 7744 77		G6011
addation heatment delivery, 3 or more separate freatment areas, custom blocking, tangential orts, wedges, rotational beam, compensators, electron beam; 11-19MeV G6013 addation treatment delivery, 3 or more separate freatment areas, custom blocking, tangential orts, wedges, rotational beam, compensators, electron beam; 20MeV or greater G6014 addation treatment delivery, 3 or more separate freatment areas, custom blocking, tangential orts, wedges, rotational beam, compensators, electron beam; 20MeV or greater G6014 addation treatment delivery, 3 or more separate freatment areas, custom blocking, tangential orts, wedges, rotational beam, compensators, electron beam; 20MeV or greater G6014 addation treatment delivery, 3 or more separate freatment session 77424 tracportative radiation treatment delivery, x-ray, single treatment session 77425 tracportative radiation treatment delivery, electrons, single treatment session 77426 tracportative radiation treatment delivery, electrons, single treatment session 77427 tracportative radiation treatment delivery, electrons, single treatment session 77426 tracportative radiation treatment delivery, electrons, single treatment session 77427 tracportative radiation treatment delivery, electrons, single treatment session 77428 tracportative radiation source application; complex 77480 tracportative radiation source application; complex 77491 tracportative radiations of treatment delivery (and or a capture delivery) includes basic assimetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple sions with the performed; and the series of the ser		
adiation freatment delivery, 3 or more separate treatment areas, custom blocking, tangential or fist, wedges, rotational beam, compensators, electron beam; 11-19MeV Genty therapy Traceperative radiation treatment delivery, and the separate treatment areas, custom blocking, tangential or separate treatment areas, custom blocking, tangential or separate treatment delivery areas or greater Genty therapy Traceperative radiation treatment delivery, electrons, single treatment session Traceperative radiation freatment delivery, electrons, single treatment session Traceperative radiation of radioelement solution (includes 3 months follow-up care) Traceperative radiation source application; intermediate Traceperative radiation source application in the service of the properation of the performed; lesion diameter up to 2.0 cm or 1 channel Traceperative radiation source application of the service radiation of the performed; intermediate rever 2.0 cm and 2 or more channels, or multiple Traceperative radiations and the service radiation of the service radiation of the performed; intermediate interstitial or intracevitary brachytherapy. Traceperative radiations are represented to the service radiation of intraceperative properative radiations of the performed; interestitial or intracevitary brachytherapy. Traceperative radiation source application, complex, includes supervision, handling, loading of diations ource, when performed; over 12 chan		G6012
orts, wedges, rotational beam, compensators, electron beam; 11-19MeV Geol Standard in treatment delivery, 3 or more separate treatment areas, custom blocking, tangential orts, wedges, rotational beam, compensators, electron beam; 20MeV or greater Geol 14 Tachytherapy Traoperative radiation treatment delivery, x-ray, single treatment session 77425 Traoperative radiation treatment delivery, electrons, single treatment session 77425 Traoperative radiation treatment delivery, electrons, single treatment session 77425 Traoperative radiation source application; simple 77761 Tracavitary radiation source application; simple 77762 Tracavitary radiation source application; complex 77763 Tracavitary radiation source application; complex 77764 Tracavitary radiation source application; complex 77765 Tracavitary radiation source application; complex 77766 Tracavitary radiation source application; complex 77767 Tracavitary radiation source application; complex 77768 Tracavitary radiation source application; complex 77769 Tracavitary radiation source application; complex 77769 Tracavitary radiation source application; complex 77760 Tracavitary radiation source application; complex 77760 Tracavitary radiation source application; complex 77760 Tracavitary radiation source application; complex includes basic absine the surface of tracavitary brachytherapy, and the surface application of the surface application, complex, includes supervision, handling, loading of diation source, when performed; 2-12 channels Tracevitary and tracevitary brachytherapy, and the surface application, per fraction, includes basic application of low dose rate radionuclide interstitial or intracavitary brachytherapy, and the surface application of low dose rate radionuclide interstitial or intracavitary brachytherapy, and the surface application, per fraction, includes basic application of low dose rate radionuclide source application, per fraction, includes basic application of low dose rate radionuclides source application, per fraction, includes ba		
adiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential orts, wedges, rotational beam, compensators, electron beam; 20MeV or greater Compensator Compensator		G6013
chytherapy traoperative radiation treatment delivery, x-ray, single treatment session 77425 traoperative radiation treatment delivery, electrons, single treatment session 77425 traoperative radiation treatment delivery, electrons, single treatment session 77425 tracoperative radiation source delivery, electrons, single treatment session 77425 tracovitary radiation source application; simple 77750 tracovitary radiation source application; simple 77761 tracovitary radiation source application; complex 77763 tracovitary radiation source application; complex 77764 tracovitary radiation source application; complex 77766 tracovitary radiation source application; complex 800 tracovitary brachytherapy, includes basic simetry, when performed; 1 channel 77768 to simetry, when performed; 1 channel 77770 tracovitary products basic dosimetry, when performed; 1 channel 77770 tracovitary products 77771 tracovitary products 77771 tracovitary products 77771 tracovitary products 77771 tracovitary products 77772 tracovitary products 77772 tracovitary products 77772 tracovitary products 77772 tracovitary products 77773 tracovitary products 777		
cachylherapy Iracoperative radiation freatment delivery, x-ray, single treatment session 77424 Iracoperative radiation freatment delivery, electrons, single treatment session 77425 Iusion or instillation of radioelement solution (includes 3 months follow-up care) 77750 Iusion or instillation of radioelement solution (includes 3 months follow-up care) 77750 Iracavitary radiation source application; simple 77761 Iracavitary radiation source application; intermediate 77762 Iracavitary radiation source application; complex 77763 Iracavitary radiation source application; complex 77763 Iracavitary radiation source application; complex 77764 Iracavitary radiation source application; complex 77765 Iracavitary when performed; lesion diameter up to 2.0 cm or 1 channel 77767 Iracavitary, when performed; lesion diameter up to 2.0 cm or 1 channel 77767 Iracavitary, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple 77768 Iracavitary, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple 77768 Iracavitary brachylherapy, includes basic dosimetry, when performed; 1 channel 77770 Iracavitary brachylherapy, 77770 Iracavitary brachylherapy, 77771 Iracavitary brachylherapy, 77771 Iracavitary brachylherapy, 77771 Iracavitary brachylherapy, 77772 Iracavitary brachylherapy, 77773 Iracavitary brachylh		G6014
tracoperative radiation treatment delivery, x-ray, single treatment session 77425 tracoperative radiation treatment delivery, electrons, single treatment session 77425 tracovitary radiation treatment solution (includes 3 months follow-up care) 77750 tracovitary radiation source application; simple 77761 tracovitary radiation source application; simple 77762 tracovitary radiation source application; simple 77763 months after a source application; simple 77763 months after a source application; simple 77763 months after a source application; complex 77764 simple performed; lesion diameter up to 2.0 cm or 1 channel 77767 simple 77767 months after a source after a source and a source a part of the source	orts, wedges, rotational beam, compensators, electron beam; 20MeV or greater	
tracoperative radiation treatment delivery, x-ray, single treatment session 77425 tracoperative radiation treatment delivery, electrons, single treatment session 77425 tracovitary radiation treatment solution (includes 3 months follow-up care) 77750 tracovitary radiation source application; simple 77761 tracovitary radiation source application; simple 77762 tracovitary radiation source application; simple 77763 months after a source application; simple 77763 months after a source application; simple 77763 months after a source application; complex 77764 simple performed; lesion diameter up to 2.0 cm or 1 channel 77767 simple 77767 months after a source after a source and a source a part of the source		
tracoperative radiation treatment delivery, x-ray, single treatment session 77425 tracoperative radiation treatment delivery, electrons, single treatment session 77425 tracovitary radiation treatment solution (includes 3 months follow-up care) 77750 tracovitary radiation source application; simple 77761 tracovitary radiation source application; simple 77762 tracovitary radiation source application; simple 77763 months after a source application; simple 77763 months after a source application; simple 77763 months after a source application; complex 77764 simple performed; lesion diameter up to 2.0 cm or 1 channel 77767 simple 77767 months after a source after a source and a source a part of the source	rachytherapy	
tracoperative radiation treatment delivery, electrons, single treatment session 77425 tracovitary radiation source application; simple 177760 tracavitary radiation source application; simple 177761 tracavitary radiation source application; complex 17762 tracavitary radiation source application; complex 17763 tracavitary radiation source application; complex 177663 tracavitary tradiation source application; complex 177664 tracavitary brachytherapy, includes basic 177665 tracavitary brachytherapy, includes basic 177666 tracavitary brachytherapy, includes basic 177667 tracavitary brachytherapy, includes basic 177668 tracavitary brachytherapy, includes basic 177688 tracavitary brachytherapy, includes basic 177688 tracavitary brachytherapy, includes basic 177790 tracavitary brachytherapy, includes basic 177790 tracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel 177791 tracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels 177792 tracavitary brachytherapy, includes supervision, handling, loading of 177792 tracavitary brachytherapy, interstitial or intracavitary brachytherapy, includes basic 177798 diation source, when performed 177897 diation source application, or low dose rate radionuclide source 177897 diation source, when performed 177897 diation source application, or low dose rate radionuclide source 177897 diation source application or low dose rate radionuclide source 177897 diation source application or low dose rate radionuclide source 17789 diation source application or low dose rate radionuclide source 1	ntraoperative radiation treatment delivery, x-ray, single treatment session	77424
tracavitary radiation source application; simple recovitary radiation source application; intermediate recovitary radiation source, when performed; lesion diameter over 2.0 cm or 1 channel remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 1 channel remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 2-12 channels remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 2-12 channels restitial radiation source application, complex, includes supervision, handling, loading of diation source, when performed race application of low dose rate radionuclide source gh dose rate electonic brachytherapy, skin surface application, per fraction, includes basic simetry, when performed gh dose rate electonic brachytherapy, interstitial or intracavitary treatment, per fraction, cludes basic dosimetry, when performed w dose rate (LDR) prostate brachytherapy services, composite rate RI rensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when reformed; complex tensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and reportedly modulated beams, binary, dynamic MLC, per treatment session rore high resolution (milled or cast) compensator, convergent beam modulated fields, per definition freatme	ntraoperative radiation treatment delivery, electrons, single treatment session	77425
tracavitary radiation source application; intermediate 77762 tracavitary radiation source application; complex 77763 morba differioading high dose rate radionuclide skin surface brachytherapy, includes basic simetry, when performed; lesion diameter up to 2.0 cm or 1 channel 77767 simetry, when performed; lesion diameter up to 2.0 cm or 1 channel 77768 simetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple sions 77768 sions 77770 simetry when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple sions 77770 simetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple sions 77770 simetry when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple sions 77770 simetry when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple sions 77770 simetry when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple sions 77770 simetry when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple sions 77770 simetry when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple sions 77771 simetry brachytherapy, 77772 cludes basic dosimetry, when performed; lesion diameter diamet	nfusion or instillation of radioelement solution (includes 3 months follow-up care)	77750
tracavitary radiation source application; complex remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic ssimetry, when performed; lesion diameter up to 2.0 cm or 1 channel remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic ssimetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple sicions remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 1 channel remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 2 channels remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 2-12 channels remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; over 12 channels remote afterloading high dose rate radionuclide supervision, handling, loading of diation source application, complex, includes supervision, handling, loading of diation source, when performed rface application of low dose rate radionuclide source gh dose rate electonic brachytherapy, skin surface application, per fraction, includes basic simetry, when performed gh dose rate electonic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed gh dose rate electonic brachytherapy, interstitial or intracavitary treatment, per fraction, 03951 cludes basic dosimetry, when performed Goules basic dosimetry, when performed gh dose rate electonic brachytherapy services, composite rate Goules RI remote afterloading high dose rate radionuclide source ghand services application of low dose rate radionuclide source ghand services application of low dose rate radionuclide source ghand services application of low dose rate radionuclide source ghand services application of low dose rate radionuclide source ghand services app	ntracavitary radiation source application; simple	77761
emote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic posimetry, when performed; lesion diameter up to 2.0 cm or 1 channel remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic posimetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple sions remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 1 channel remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 2-12 channels remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 2-12 channels restricted basic dosimetry, when performed; over 12 channels restricted a polication source application, complex, includes supervision, handling, loading of diation source, when performed radionuclide source gh dose rate redectonic brachytherapy, skin surface application, per fraction, includes basic solimetry, when performed gh dose rate electonic brachytherapy, skin surface application, per fraction, includes basic solimetry, when performed gh dose rate electonic brachytherapy, interstitial or intracavitary treatment, per fraction, constituted basic solimetry, when performed gh dose rate electonic brachytherapy, interstitial or intracavitary treatment, per fraction, constituted basic dosimetry, when performed gh dose rate electonic brachytherapy services, composite rate RI RI RI RI RI RI RI RI RI R	ntracavitary radiation source application; intermediate	77762
osimetry, when performed; lesion diameter up to 2.0 cm or 1 channel 77768 mote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic osimetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple sions mote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 1 channel mote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 2-12 channels mote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 2-12 channels mote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; over 12 channels terstitial radiation source application, complex, includes supervision, handling, loading of diation source, when performed rface application of low dose rate radionuclide source gh dose rate electonic brachytherapy, skin surface application, per fraction, includes basic osimetry, when performed gh dose rate electonic brachytherapy, interstitial or intracavitary treatment, per fraction, cludes basic dosimetry, when performed w dose rate (LDR) prostate brachytherapy services, composite rate RX tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when erformed; simple tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when erformed; simple tensity modulated readiation treatment delivery (IMRT), includes guidance and tracking, when erformed simple tensity modulated beams, binary, dynamic MLC, per treatment session G6015 Trass G6016 G6016 G6016 G6016 G6017 G77423	ntracavitary radiation source application; complex	77763
posimetry, when performed; lesion diameter up to 2.0 cm or 1 channel armote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic asimetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple armote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 1 channel armote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 2-12 channels armote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; over 12 channels armote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; over 12 channels armote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; over 12 channels artoric application of low dose rate radionuclide supervision, handling, loading of diation source, when performed artoric application of low dose rate radionuclide source gh dose rate electonic brachytherapy, skin surface application, per fraction, includes basic asimetry, when performed and dose rate electonic brachytherapy, interstitial or intracavitary treatment, per fraction, cludes basic dosimetry, when performed and dose rate electonic brachytherapy, interstitial or intracavitary treatment, per fraction, cludes basic dosimetry, when performed and dose rate electonic brachytherapy services, composite rate RI tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when artoric complex tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when artoric complex tensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and more proposition (milled or cast) compensator, convergent beam modulated fields, per complex treatment delivery of invers	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic	77747
pasimetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple sions remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 1 channel remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 2-12 channels remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 2-12 channels remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; over 12 channels restritial radiation source application, complex, includes supervision, handling, loading of diation source, when performed rface application of low dose rate radionuclide source gh dose rate electonic brachytherapy, skin surface application, per fraction, includes basic osimetry, when performed gh dose rate electonic brachytherapy, interstitial or intracavitary treatment, per fraction, cludes basic dosimetry, when performed w dose rate (LDR) prostate brachytherapy services, composite rate RX rensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when afformed; simple rensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when afformed; complex rensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and mporally modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and mporally modulated beams, binary, dynamic MLC, per treatment session representative per formed delivery (modulated fields, per delivery of inverse planned treatment using 3 or one high resolution (milled or cast) compensator, convergent beam modulated fields, per defendent session	dosimetry, when performed; lesion diameter up to 2.0 cm or 1 channel	///0/
stions amote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 1 channel amote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 2-12 channels amote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 2-12 channels amote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; over 12 channels terstitial radiation source application, complex, includes supervision, handling, loading of diation source, when performed frace application of low dose rate radionuclide source grid dose rate electonic brachytherapy, skin surface application, per fraction, includes basic assimetry, when performed grid dose rate electonic brachytherapy, interstitial or intracavitary treatment, per fraction, cludes basic dosimetry, when performed w dose rate (LDR) prostate brachytherapy services, composite rate Go458 RI tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when erformed; simple tensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and mporally modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and mporally modulated beams, binary, dynamic MLC, per treatment session Go6015 compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or ore high resolution (milled or cast) compensator, convergent beam modulated fields, per core high resolution (milled or cast) compensator, convergent beam modulated fields, per gore high resolution treatment delivery; 1 or more isocenter(s) with coplanar or non-	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic	
contest afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 1 channel mote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 2-12 channels mote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; over 12 channels terstitial radiation source application, complex, includes supervision, handling, loading of diation source, when performed complex, includes supervision, handling, loading of diation source, when performed race application of low dose rate radionuclide source placetion, per fraction, includes basic placeting of low dose rate electonic brachytherapy, skin surface application, per fraction, includes basic placeting of dose rate electonic brachytherapy, interstitial or intracavitary treatment, per fraction, cludes basic dosimetry, when performed we dose rate electonic brachytherapy services, composite rate electonic brachyt	dosimetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple	77768
cludes basic dosimetry, when performed; 1 channel 77771 77772 77772 77772 77772 77772 77772 77773 77772 77772 77772 77772 77773 77772 77773 77772 77773 77774 77778 77778 77778 77778 77778 77778 77778 7778	esions	
cludes basic dosimetry, when performed; 1 channels emote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; 2-12 channels emote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; over 12 channels derstitial radiation source application, complex, includes supervision, handling, loading of diation source, when performed rface application of low dose rate radionuclide source gh dose rate electonic brachytherapy, skin surface application, per fraction, includes basic osimetry, when performed gh dose rate electonic brachytherapy, interstitial or intracavitary treatment, per fraction, cludes basic dosimetry, when performed we dose rate (LDR) prostate brachytherapy services, composite rate RT		77770
cludes basic dosimetry, when performed; 2-12 channels mote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; over 12 channels terstitial radiation source application, complex, includes supervision, handling, loading of diation source, when performed rface application of low dose rate radionuclide source gh dose rate electonic brachytherapy, skin surface application, per fraction, includes basic osimetry, when performed gh dose rate electonic brachytherapy, interstitial or intracavitary treatment, per fraction, cludes basic dosimetry, when performed whose rate (LDR) prostate brachytherapy services, composite rate Go458 IRI tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex tensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and amporally modulated beams, binary, dynamic MLC, per treatment session Go015 core high resolution (milled or cast) compensator, convergent beam modulated fields, per performed; session Sultron Therapy gh energy neutron radiation treatment delivery; 1 or more isocenter(s) with coplanar or non-	ncludes basic dosimetry, when performed; 1 channel	77770
cludes basic dosimetry, when performed; 2-12 channels emote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, cludes basic dosimetry, when performed; over 12 channels derstitial radiation source application, complex, includes supervision, handling, loading of diation source, when performed frace application of low dose rate radionuclide source gly dose rate electonic brachytherapy, skin surface application, per fraction, includes basic assimetry, when performed gly dose rate electonic brachytherapy, interstitial or intracavitary treatment, per fraction, cludes basic dosimetry, when performed gly dose rate electonic brachytherapy, interstitial or intracavitary treatment, per fraction, cludes basic dosimetry, when performed we dose rate (LDR) prostate brachytherapy services, composite rate Gouts INT lensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple lensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex lensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and mporally modulated beams, binary, dynamic MLC, per treatment session Gouts between the session modulation freatment delivery of inverse planned treatment using 3 or locatment session Gouts Gouts		77771
cludes basic dosimetry, when performed; over 12 channels terstitial radiation source application, complex, includes supervision, handling, loading of diation source, when performed rface application of low dose rate radionuclide source gh dose rate electonic brachytherapy, skin surface application, per fraction, includes basic osimetry, when performed gh dose rate electonic brachytherapy, interstitial or intracavitary treatment, per fraction, cludes basic dosimetry, when performed whose rate (LDR) prostate brachytherapy services, composite rate Go458 IRI tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex tensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and mporally modulated beams, binary, dynamic MLC, per treatment session ompensator-based beam modulation treatment delivery of inverse planned treatment using 3 or ore high resolution (milled or cast) compensator, convergent beam modulated fields, per performed; session sultron Therapy gh energy neutron radiation treatment delivery; 1 or more isocenter(s) with coplanar or non-	ncludes basic dosimetry, when performed; 2-12 channels	,,,,,
cludes basic dosimetry, when performed; over 12 channels learstitial radiation source application, complex, includes supervision, handling, loading of diation source, when performed frace application of low dose rate radionuclide source gh dose rate electonic brachytherapy, skin surface application, per fraction, includes basic osimetry, when performed gh dose rate electonic brachytherapy, interstitial or intracavitary treatment, per fraction, cludes basic dosimetry, when performed whose rate electonic brachytherapy services, composite rate Gouper to the state of the s		77772
diation source, when performed rface application of low dose rate radionuclide source gh dose rate electonic brachytherapy, skin surface application, per fraction, includes basic osimetry, when performed gh dose rate electonic brachytherapy, interstitial or intracavitary treatment, per fraction, cludes basic dosimetry, when performed aw dose rate (LDR) prostate brachytherapy services, composite rate Go458 RT tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when erformed; simple tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when erformed; complex tensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and mporally modulated beams, binary, dynamic MLC, per treatment session one high resolution (milled or cast) compensator, convergent beam modulated fields, per core high resolution (milled or cast) compensator, convergent beam modulated fields, per core high resolution reatment delivery; 1 or more isocenter(s) with coplanar or non- 77423		77772
race application of low dose rate radionuclide source gh dose rate electonic brachytherapy, skin surface application, per fraction, includes basic osimetry, when performed gh dose rate electonic brachytherapy, interstitial or intracavitary treatment, per fraction, cludes basic dosimetry, when performed we dose rate (LDR) prostate brachytherapy services, composite rate RET tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when erformed; simple tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when erformed; complex tensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and mporally modulated beams, binary, dynamic MLC, per treatment session compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or one high resolution (milled or cast) compensator, convergent beam modulated fields, per corrections in the performed of the		77778
gh dose rate electonic brachytherapy, skin surface application, per fraction, includes basic osimetry, when performed gh dose rate electonic brachytherapy, interstitial or intracavitary treatment, per fraction, cludes basic dosimetry, when performed gw dose rate (LDR) prostate brachytherapy services, composite rate gracing with the strict of the stri		
gh dose rate electonic brachytherapy, interstitial or intracavitary treatment, per fraction, cludes basic dosimetry, when performed wo dose rate (LDR) prostate brachytherapy services, composite rate G0458 IRT Itensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when erformed; simple tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when erformed; complex tensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and mporally modulated beams, binary, dynamic MLC, per treatment session G6015 G6016 G6016 G6016 G6017 G6016 G77423		77789
gh dose rate electonic brachytherapy, interstitial or intracavitary treatment, per fraction, cludes basic dosimetry, when performed w dose rate (LDR) prostate brachytherapy services, composite rate G0458 IRT tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when erformed; simple tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when erformed; complex tensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and mporally modulated beams, binary, dynamic MLC, per treatment session G6015 Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or ore high resolution (milled or cast) compensator, convergent beam modulated fields, per G6016 Contractive treatment using 3 or ore high resolution (milled or cast) compensator, convergent beam modulated fields, per G6016 Contractive treatment using 3 or ore high resolution (milled or cast) compensator, convergent beam modulated fields, per G6016 Contractive treatment using 3 or ore high resolution (milled or cast) compensator, convergent beam modulated fields, per G6016 Contractive treatment using 3 or or ore high resolution (milled or cast) compensator, convergent beam modulated fields, per G6016 Contractive treatment using 3 or or ore high resolution (milled or cast) compensator, convergent beam modulated fields, per G7423		0394T
cludes basic dosimetry, when performed w dose rate (LDR) prostate brachytherapy services, composite rate G0458 RT tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when erformed; simple tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when erformed; complex tensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and mporally modulated beams, binary, dynamic MLC, per treatment session G6015 Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or ore high resolution (milled or cast) compensator, convergent beam modulated fields, per G6016 Control Therapy Generally modulation treatment delivery; 1 or more isocenter(s) with coplanar or non-		00711
IRI tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when erformed; simple tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when erformed; simple tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when erformed; complex tensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and mporally modulated beams, binary, dynamic MLC, per treatment session compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or ore high resolution (milled or cast) compensator, convergent beam modulated fields, per G6016 eatment session Futron Therapy gh energy neutron radiation treatment delivery; 1 or more isocenter(s) with coplanar or non-		0395T
tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when reformed; simple tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when reformed; complex tensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and modulated beams, binary, dynamic MLC, per treatment session representation or performed beam modulation treatment delivery of inverse planned treatment using 3 or or ore high resolution (milled or cast) compensator, convergent beam modulated fields, per resolution (milled or cast) compensator, convergent beam modulated fields, per resolution treatment delivery; 1 or more isocenter(s) with coplanar or non-		
tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when erformed; simple tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when erformed; complex tensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and modulated beams, binary, dynamic MLC, per treatment session compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or or ore high resolution (milled or cast) compensator, convergent beam modulated fields, per G6016 tentron Therapy gh energy neutron radiation treatment delivery; 1 or more isocenter(s) with coplanar or non-	ow dose rate (LDR) prostate brachytherapy services, composite rate	G0458
tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when erformed; simple tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when erformed; complex tensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and modulated beams, binary, dynamic MLC, per treatment session compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or or ore high resolution (milled or cast) compensator, convergent beam modulated fields, per G6016 tentron Therapy gh energy neutron radiation treatment delivery; 1 or more isocenter(s) with coplanar or non-		
reformed; simple tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when reformed; complex tensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and mporally modulated beams, binary, dynamic MLC, per treatment session ompensator-based beam modulation treatment delivery of inverse planned treatment using 3 or ore high resolution (milled or cast) compensator, convergent beam modulated fields, per centron Therapy gh energy neutron radiation treatment delivery; 1 or more isocenter(s) with coplanar or non-		
tensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex tensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and modulated beams, binary, dynamic MLC, per treatment session compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or or ore high resolution (milled or cast) compensator, convergent beam modulated fields, per attention session Seutron Therapy gh energy neutron radiation treatment delivery; 1 or more isocenter(s) with coplanar or non-	· · · · · · · · · · · · · · · · · · ·	77385
reformed; complex tensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and mporally modulated beams, binary, dynamic MLC, per treatment session compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or ore high resolution (milled or cast) compensator, convergent beam modulated fields, per control Therapy gh energy neutron radiation treatment delivery; 1 or more isocenter(s) with coplanar or non-		
tensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and mporally modulated beams, binary, dynamic MLC, per treatment session empensator-based beam modulation treatment delivery of inverse planned treatment using 3 or ore high resolution (milled or cast) compensator, convergent beam modulated fields, per atment session Seutron Therapy gh energy neutron radiation treatment delivery; 1 or more isocenter(s) with coplanar or non-		77386
mporally modulated beams, binary, dynamic MLC, per treatment session compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or ore high resolution (milled or cast) compensator, convergent beam modulated fields, per catment session Sutron Therapy gh energy neutron radiation treatment delivery; 1 or more isocenter(s) with coplanar or non-		
compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or ore high resolution (milled or cast) compensator, convergent beam modulated fields, per G6016 eatment session Eutron Therapy gh energy neutron radiation treatment delivery; 1 or more isocenter(s) with coplanar or non-		G6015
ore high resolution (milled or cast) compensator, convergent beam modulated fields, per G6016 eatment session Eutron Therapy gh energy neutron radiation treatment delivery; 1 or more isocenter(s) with coplanar or non-		
eatment session Eutron Therapy gh energy neutron radiation treatment delivery; 1 or more isocenter(s) with coplanar or non-	· · · · · · · · · · · · · · · · · · ·	C/01/
eutron Therapy gh energy neutron radiation treatment delivery; 1 or more isocenter(s) with coplanar or non-		G6016
gh energy neutron radiation treatment delivery; 1 or more isocenter(s) with coplanar or non-	IEGIIIIGIII 3E33IOII	
gh energy neutron radiation treatment delivery; 1 or more isocenter(s) with coplanar or non-	Journa Thorany	
- //Δ/3		
volanar acometry with blocking and / or wedge, and / /or compositor(s)		77.400
	oplanar geometry with blocking and / or wedge, and / /or compensator(s)	//423

Proton Beam	
Proton treatment delivery; simple, without compensation	77520
Proton treatment delivery; simple, with compensation	77522
Proton treatment delivery; intermediate	77523
Proton treatment delivery; complex	77525
Stereotactic Radiosurgery	
Thoracic target(s) delineation for stereotactic body radiation therapy (SRS/SBRT), (photon or particle beam), entire course of treatment	32701

Stereotactic Radiosurgery	
Thoracic target(s) delineation for stereotactic body radiation therapy (SRS/SBRT), (photon or particle beam), entire course of treatment	32701
Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 simple cranial lesion	61796
Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 complex cranial lesion	61798
Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 spinal lesion	63620
Radiation treatment delivery, stereotactic radiosurgery (SRS), complete course of treatment of cranial lesion(s) consisting of 1 session; multi-source Cobalt 60 based	77371
Radiation treatment delivery, stereotactic radiosurgery (SRS), complete course of treatment of cranial lesion(s) consisting of 1 session; linear accelerator based	77372
Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions	77373
Image guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session, or first session of fractionated treatment	G0339
Image guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum five sessions per course of treatment	G0340

MEDICAL ONCOLOGY

NOTE: Procedure codes indicated for treatment of medical oncology diagnoses only.

NOTE: All medical oncology drugs must be submitted for review, including drugs with codes not otherwise specified.

otherwise specified. HCPCS	
LUTETIUM LU 177, DOTATATE, THERAPEUTIC, 1 MILLICURIE	A9513
NDIUM IN-111 IBRITUMOMAB TIUXETAN, DIAGNOSTIC, PER STUDY DOSE, UP TO 5 MILLICURIES	A9542
YTTRIUM Y-90 IBRITUMOMAB TIUXETAN, THERAPEUTIC, PER TREATMENT DOSE, UP TO 40 MILLICURIES	A9543
ODINE I-131, IOBENGUANE, 1 MILLICURIE	A9590
RADIUM RA-223 DICHLORIDE, THERAPEUTIC, PER MICROCURIE	A9606
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, THERAPEUTIC, 1 MILLICURIE	A9607
RADIOPHARMACEUTICAL, THERAPEUTIC, NOT OTHERWISE CLASSIFIED	A9699
ndicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell ymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and nigh-grade B-cell lymphoma after two or more lines of systemic therapy.	C9155
NJECTION, BEVACIZUMAB, 0.25 MG	C9257
NJECTION, GLUCARPIDASE, 10 UNITS	C9293
JNCLASSIFIED DRUGS OR BIOLOGICALS	C9399
NJECTION, ALEMTUZUMAB, 1 MG	J0202
NJECTION, AMIFOSTINE, 500 MG	J0207
NJECTION, BUSULFAN, 1 MG	J0594
NJECTION, LEUCOVORIN CALCIUM, PER 50 MG	J0640
NJECTION, LEVOLEUCOVORIN, NOT OTHERWISE SPECIFIED, 0.5 MG	J0641
NJECTION, LEVOLEUCOVORIN (KHAPZORY), 0.5 MG	J0642
njection, darbepoetin alfa, 1 microgram (non-esrd use)	J0881
njection, epoetin alfa, (for non-esrd use), 1000 units	J0885
njectin, epoetin beta, 1 microgram, (for non esrd use)	J0888
njection, decitabine (sun pharma) not therapeutically equivalent to j0894, 1 mg	J0893
NJECTION, DECITABINE, 1 MG	J0894
njection, denosumab, 1 mg	J0897
NJECTION, FILGRASTIM (G-CSF), EXCLUDES BIOSIMILARS, 1 MICROGRAM	J1442
NJECTION, TBO-FILGRASTIM, 1 MICROGRAM	J1447
NJECTION, TRILACICLIB, 1 MG	J1448
njection, eflapegrastim-xnst, 0.1 mg	J1449
NJECTION, FOSNETUPITANT 235 MG AND PALONOSETRON 0.25 MG	J1454
njection, fosaprepitant (teva), not therapeutically equivalent to j1453, 1 mg	J1456
njection, immune globulin, (gammaplex), intravenous, non-lyophilized (e.g. liquid), 500 mg	J1557
NJECTION, IMMUNE GLOBULIN, (GAMUNEX-C/GAMMAKED), NON-LYOPHILIZED (E.G. LIQUID), 500 MG	J1561
NJECTION, IMMUNE GLOBULIN, INTRAVENOUS, LYOPHILIZED (E.G. POWDER), NOT OTHERWISE SPECIFIED, 500 MG	J1566

HCPCS (cont)	
INJECTION, IMMUNE GLOBULIN, (GAMMAGARD LIQUID), NON-LYOPHILIZED, (E.G. LIQUID), 500 MG	J1569
INJECTION, IMMUNE GLOBULIN, (FLEBOGAMMA/FLEBOGAMMA DIF), INTRAVENOUS, NON-LYOPHILIZED (E.G. LIQUID), 500 MG	J1572
Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg	J1576
INJECTION, LANREOTIDE, 1 MG	J1930
INJECTION, LANREOTIDE, (CIPLA), 1 MG	J1932
INJECTION, LEUPROLIDE ACETATE (FOR DEPOT SUSPENSION), PER 3.75 MG	J1950
LEUPROLIDE INJECTABLE, CAMCEVI, 1 MG	J1952
INJECTION, OCTREOTIDE, DEPOT FORM FOR INTRAMUSCULAR INJECTION, 1 MG	J2353
INJECTION, OCTREOTIDE, NON-DEPOT FORM FOR SUBCUTANEOUS OR INTRAVENOUS INJECTION, 25 MCG	J2354
INJECTION, PAMIDRONATE DISODIUM, PER 30 MG	J2430
INJECTION, PALONOSETRON HCL, 25 MCG	J2469
INJECTION, PEGFILGRASTIM, EXCLUDES BIOSIMILAR, 0.5 MG	J2506
INJECTION, PLERIXAFOR, 1 MG	J2562
INJECTION, ROMIPLOSTIM, 10 MICROGRAMS	J2796
INJECTION, ROLAPITANT, 0.5 MG	J2797
INJECTION, SARGRAMOSTIM (GM-CSF), 50 MCG	J2820 J2860
INJECTION, SILTUXIMAB, 10 MG INJECTION, TOCILIZUMAB, 1 MG	J3262
INJECTION, TOCKLIZOMAB, TIMG INJECTION, TRIPTORELIN PAMOATE, 3.75 MG	J3315
INJECTION, TRIPTORELIN, EXTENDED-RELEASE, 3.75 MG	J3316
INJECTION, VEDOLIZUMAB, 1 MG	J3380
INJECTION, ZOLEDRONIC ACID, 1 MG	J3489
UNCLASSIFIED BIOLOGICS	J3590
LYMPHOCYTE IMMUNE GLOBULIN, ANTITHYMOCYTE GLOBULIN, EQUINE, PARENTERAL, 250 MG	J7504
LYMPHOCYTE IMMUNE GLOBULIN, ANTITHYMOCYTE GLOBULIN, RABBIT, PARENTERAL, 25 MG	J7511
SIROLIMUS, ORAL, 1 MG	J7520
EVEROLIMUS, ORAL, 0.25 MG	J7527
BUSULFAN; ORAL, 2 MG	J8510
CAPECITABINE, ORAL, 150 MG	J8520
CAPECITABINE, ORAL, 500 MG	J8521
CYCLOPHOSPHAMIDE; ORAL, 25 MG	J8530
ETOPOSIDE; ORAL, 50 MG	J8560
ANTIEMETIC DRUG, ORAL, NOT OTHERWISE SPECIFIED	J8597
METHOTREXATE; ORAL, 2.5 MG	J8610
TEMOZOLOMIDE, ORAL, 5 MG TOPOTECAN, ORAL, 0.25 MG	J8700 J8705
PRESCRIPTION DRUG, ORAL, CHEMOTHERAPEUTIC, NOS	J8999
INJECTION, DOXORUBICIN HYDROCHLORIDE, 10 MG	J9000
INJECTION, ALDESLEUKIN, PER SINGLE USE VIAL	J9015
INJECTION, ARSENIC TRIOXIDE, 1 MG	J9017
INJECTION, ASPARAGINASE (ERWINAZE), 1,000 IU	J9019
INJECTION, ASPARAGINASE, RECOMBINANT, (RYLAZE), 0.1 MG	J9021
INJECTION, ATEZOLIZUMAB, 10 MG	J9022
INJECTION, AVELUMAB, 10 MG	J9023
INJECTION, AZACITIDINE, 1 MG	J9025
INJECTION, CLOFARABINE, 1 MG	J9027
Injection, nadofaragene firadenovec-vncg, per therapeutic dose	J9029
BCG LIVE INTRAVESICAL INSTILLATION, 1 MG	J9030
INJECTION, BELINOSTAT, 10 MG	J9032
INJECTION, BENDAMUSTINE HCL, 1 MG	J9033
INJECTION, BENDAMUSTINE HCL (BENDEKA), 1 MG	J9034
INJECTION, BEVACIZUMAB, 10 MG	J9035
INJECTION, BENDAMUSTINE HYDROCHLORIDE, (BELRAPZO), 1 MG	J9036
INJECTION, BELANTAMAB MAFODONTIN-BLMF, 0.5 MG	J9037 J9039
INJECTION, BLINATUMOMAB, 1 MICROGRAM INJECTION, BLEOMYCIN SULFATE, 15 UNITS	J9039 J9040
INJECTION, BLEOMYCIN SULFAIE, 15 UNITS INJECTION, BORTEZOMIB (VELCADE), 0.1 MG	J9040 J9041
INJECTION, BORTEZOMIB (VELCADE), 0.1 MG INJECTION, BRENTUXIMAB VEDOTIN, 1 MG	J9042
INJECTION, CABAZITAXEL, 1 MG	J9043
INJECTION, CARBOPLATIN, 50 MG	J9045
Injection, bortezomib, (dr. reddy's), not therapeutically equivalent to J9041, 0.1 mg	J9046
INJECTION, CARFILZOMIB, 1 MG	J9047

njection, bortezomib (fresenius kabi), not therapeutically equivalent to J9041, 0.1 mg	J9048
njection, bortezomib (hospira), not therapeutically equivalent to J9041, 0.1 mg	J9048 J9049
NJECTION, CARMUSTINE, 100 MG	J9050
ndicated for the treatment of adult patients with multiple myeloma and the treatment of adult patients with mantle cell lymphoma.	J9051
NJECTION, CETUXIMAB, 10 MG	J9055
njection, bendamustine hydrochloride (vivimusta), 1 mg	J9056
njection, copanlisib, 1 mg	J9057
njection, bendamustine hydrochloride (apotex), 1 mg	J9058
njection, bendamustine hydrochloride (baxter), 1 mg	J9059
NJECTION, CISPLATIN, POWDER OR SOLUTION, 10 MG NJECTION, AMIVANTAMAB-VMJW, 2 MG	J9060 J9061
njection, mirvetuximab soravtansine-gynx, 1 mg	J9063
ndicated for the treatment of patients with castration resistant (hormone refractory) metastatic prostate cancer previously treated with a docetaxel containing regimen.	J9064
NJECTION, CLADRIBINE, PER 1 MG	J9065
CYCLOPHOSPHAMIDE, 100 MG	J9070
NJECTION, CYCLOPHOSPHAMIDE, (AUROMEDICS), 5 MG	J9071
NJECTION, CYTARABINE, 100 MG	J9100
njection, calaspargase pegol-mknl, 10 units	J9118
NJECTION, CEMIPLIMAB-RWLC, 1 MG	J9119
JECTION, DACTINOMYCIN, 0.5 MG	J9120
ACARBAZINE, 100 MG	J9130
IJECTION, DARATUMUMAB, 10 MG AND HYALURONIDASE-FIHJ IJECTION, DARATUMUMAB, 10 MG	J9144 J9145
IJECTION, DARATUMUMAB, TU MG	J9145 J9150
IJECTION, LIPOSOMAL, 1 MG DAUNORUBICIN AND 2.27 MG CYTARABINE	J9153
IJECTION, DEGARELIX, 1 MG	J9155
IJECTION, DOCETAXEL, 1 MG	J9171
IJECTION, DURVALUMAB, 10 MG	J9173
IJECTION, ELLIOTTS' B SOLUTION, 1 ML	J9175
JECTION, ELOTUZUMAB, 1 MG	J9176
JECTION, ENFORTUMAB VEDOTIN-EJFV, 0.25 MG	J9177
JECTION, EPIRUBICIN HCL, 2 MG	J9178
IJECTION, ERIBULIN MESYLATE, 0.1 MG IJECTION, ETOPOSIDE, 10 MG	J9179 J9181
IJECTION, ETOPOSIDE, TO MG	J9185
IJECTION, FLUOROURACIL, 500 MG	J9190
jection, gemcitabine hydrochloride (accord), not therapeutically equivalent to J9201, 200 mg	J9196
IJECTION, GEMCITABINE HYDROCHLORIDE, (INFUGEM), 100 MG	J9198
JECTION, FLOXURIDINE, 500 MG	J9200
IJECTION, GEMCITABINE HYDROCHLORIDE, 200 MG	J9201
	J9202
OSERELIN ACETATE IMPLANT, PER 3.6 MG	
JECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG	J9203
JECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG JECTION, MOGAMULIZUMAB-KPKC, 1 MG	J9204
JECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG JECTION, MOGAMULIZUMAB-KPKC, 1 MG JECTION, IRINOTECAN LIPOSOME, 1 MG	J9204 J9205
JECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG JECTION, MOGAMULIZUMAB-KPKC, 1 MG JECTION, IRINOTECAN LIPOSOME, 1 MG JECTION, IRINOTECAN, 20 MG	J9204 J9205 J9206
JECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG JECTION, MOGAMULIZUMAB-KPKC, 1 MG JECTION, IRINOTECAN LIPOSOME, 1 MG JECTION, IRINOTECAN, 20 MG JECTION, IXABEPILONE, 1 MG	Ј9204 Ј9205 Ј9206 Ј9207
JECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG JECTION, MOGAMULIZUMAB-KPKC, 1 MG JECTION, IRINOTECAN LIPOSOME, 1 MG JECTION, IRINOTECAN, 20 MG JECTION, IXABEPILONE, 1 MG JECTION, IFOSFAMIDE, 1 GRAM	J9204 J9205 J9206 J9207 J9208
JECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG JECTION, MOGAMULIZUMAB-KPKC, 1 MG JECTION, IRINOTECAN LIPOSOME, 1 MG JECTION, IRINOTECAN, 20 MG JECTION, IXABEPILONE, 1 MG JECTION, IFOSFAMIDE, 1 GRAM JECTION, MESNA, 200 MG	Ј9204 Ј9205 Ј9206 Ј9207
JECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG JECTION, MOGAMULIZUMAB-KPKC, 1 MG JECTION, IRINOTECAN LIPOSOME, 1 MG JECTION, IRINOTECAN, 20 MG JECTION, IXABEPILONE, 1 MG JECTION, IFOSFAMIDE, 1 GRAM JECTION, MESNA, 200 MG JECTION, EMAPALUMAB-LZSG, 1 MG	J9204 J9205 J9206 J9207 J9208 J9209
JECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG JECTION, MOGAMULIZUMAB-KPKC, 1 MG JECTION, IRINOTECAN LIPOSOME, 1 MG JECTION, IRINOTECAN, 20 MG JECTION, IXABEPILONE, 1 MG JECTION, IFOSFAMIDE, 1 GRAM JECTION, MESNA, 200 MG JECTION, EMAPALUMAB-LZSG, 1 MG JECTION, IDARUBICIN HYDROCHLORIDE, 5 MG	J9204 J9205 J9206 J9207 J9208 J9209 J9210
JECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG JECTION, MOGAMULIZUMAB-KPKC, 1 MG JECTION, IRINOTECAN LIPOSOME, 1 MG JECTION, IRINOTECAN, 20 MG JECTION, IXABEPILONE, 1 MG JECTION, IFOSFAMIDE, 1 GRAM JECTION, MESNA, 200 MG JECTION, EMAPALUMAB-LZSG, 1 MG JECTION, IDARUBICIN HYDROCHLORIDE, 5 MG JECTION, INTERFERON, ALFA-2B, RECOMBINANT, 1 MILLION UNITS JECTION, INTERFERON, ALFA-N3, (HUMAN LEUKOCYTE DERIVED), 250,000 IU	J9204 J9205 J9206 J9207 J9208 J9209 J9210 J9211 J9214 J9215
JECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG JECTION, MOGAMULIZUMAB-KPKC, 1 MG JECTION, IRINOTECAN LIPOSOME, 1 MG JECTION, IRINOTECAN, 20 MG JECTION, IXABEPILONE, 1 MG JECTION, IFOSFAMIDE, 1 GRAM JECTION, MESNA, 200 MG JECTION, EMAPALUMAB-LZSG, 1 MG JECTION, IDARUBICIN HYDROCHLORIDE, 5 MG JECTION, INTERFERON, ALFA-2B, RECOMBINANT, 1 MILLION UNITS JECTION, INTERFERON, ALFA-N3, (HUMAN LEUKOCYTE DERIVED), 250,000 IU UPROLIDE ACETATE (FOR DEPOT SUSPENSION), 7.5 MG	J9204 J9205 J9206 J9207 J9208 J9209 J9210 J9211 J9214 J9215 J9217
JECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG JECTION, MOGAMULIZUMAB-KPKC, 1 MG JECTION, IRINOTECAN LIPOSOME, 1 MG JECTION, IRINOTECAN, 20 MG JECTION, IXABEPILONE, 1 MG JECTION, IFOSFAMIDE, 1 GRAM JECTION, MESNA, 200 MG JECTION, EMAPALUMAB-LZSG, 1 MG JECTION, IDARUBICIN HYDROCHLORIDE, 5 MG JECTION, INTERFERON, ALFA-2B, RECOMBINANT, 1 MILLION UNITS JECTION, INTERFERON, ALFA-N3, (HUMAN LEUKOCYTE DERIVED), 250,000 IU UPROLIDE ACETATE (FOR DEPOT SUSPENSION), 7.5 MG	J9204 J9205 J9206 J9207 J9208 J9209 J9210 J9211 J9214 J9215 J9217 J9218
JECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG JECTION, MOGAMULIZUMAB-KPKC, 1 MG JECTION, IRINOTECAN LIPOSOME, 1 MG JECTION, IRINOTECAN, 20 MG JECTION, IXABEPILONE, 1 MG JECTION, IFOSFAMIDE, 1 GRAM JECTION, MESNA, 200 MG JECTION, EMAPALUMAB-LZSG, 1 MG JECTION, IDARUBICIN HYDROCHLORIDE, 5 MG JECTION, INTERFERON, ALFA-2B, RECOMBINANT, 1 MILLION UNITS JECTION, INTERFERON, ALFA-N3, (HUMAN LEUKOCYTE DERIVED), 250,000 IU UPROLIDE ACETATE (FOR DEPOT SUSPENSION), 7.5 MG UPROLIDE ACETATE, PER 1 MG JECTION, LURBINECTEDIN, 0.1 MG	J9204 J9205 J9206 J9207 J9208 J9209 J9210 J9211 J9214 J9215 J9217 J9218 J9223
JECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG JECTION, MOGAMULIZUMAB-KPKC, 1 MG JECTION, IRINOTECAN LIPOSOME, 1 MG JECTION, IRINOTECAN, 20 MG JECTION, IXABEPILONE, 1 MG JECTION, IFOSFAMIDE, 1 GRAM JECTION, MESNA, 200 MG JECTION, EMAPALUMAB-LZSG, 1 MG JECTION, IDARUBICIN HYDROCHLORIDE, 5 MG JECTION, INTERFERON, ALFA-2B, RECOMBINANT, 1 MILLION UNITS JECTION, INTERFERON, ALFA-N3, (HUMAN LEUKOCYTE DERIVED), 250,000 IU UPROLIDE ACETATE (FOR DEPOT SUSPENSION), 7.5 MG UPROLIDE ACETATE, PER 1 MG JECTION, LURBINECTEDIN, 0.1 MG STRELIN IMPLANT (VANTAS), 50 MG	J9204 J9205 J9206 J9207 J9208 J9209 J9210 J9211 J9214 J9215 J9217 J9218 J9223 J9225
JECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG JECTION, MOGAMULIZUMAB-KPKC, 1 MG JECTION, IRINOTECAN LIPOSOME, 1 MG JECTION, IRINOTECAN, 20 MG JECTION, IRINOTECAN, 20 MG JECTION, IFOSFAMIDE, 1 GRAM JECTION, MESNA, 200 MG JECTION, MESNA, 200 MG JECTION, EMAPALUMAB-LZSG, 1 MG JECTION, IDARUBICIN HYDROCHLORIDE, 5 MG JECTION, INTERFERON, ALFA-2B, RECOMBINANT, 1 MILLION UNITS JECTION, INTERFERON, ALFA-N3, (HUMAN LEUKOCYTE DERIVED), 250,000 IU SUPROLIDE ACETATE (FOR DEPOT SUSPENSION), 7.5 MG JECTION, LURBINECTEDIN, 0.1 MG STRELIN IMPLANT (VANTAS), 50 MG STRELIN IMPLANT (SUPPRELIN LA), 50 MG	J9204 J9205 J9206 J9207 J9208 J9209 J9210 J9211 J9214 J9215 J9217 J9218 J9223 J9225 J9226
JECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG JECTION, MOGAMULIZUMAB-KPKC, 1 MG JECTION, IRINOTECAN LIPOSOME, 1 MG JECTION, IRINOTECAN, 20 MG JECTION, IRINOTECAN, 20 MG JECTION, IFOSFAMIDE, 1 GRAM JECTION, MESNA, 200 MG JECTION, MESNA, 200 MG JECTION, EMAPALUMAB-LZSG, 1 MG JECTION, IDARUBICIN HYDROCHLORIDE, 5 MG JECTION, INTERFERON, ALFA-2B, RECOMBINANT, 1 MILLION UNITS JECTION, INTERFERON, ALFA-N3, (HUMAN LEUKOCYTE DERIVED), 250,000 IU SUPROLIDE ACETATE (FOR DEPOT SUSPENSION), 7.5 MG JECTION, LURBINECTEDIN, 0.1 MG STRELIN IMPLANT (VANTAS), 50 MG STRELIN IMPLANT (SUPPRELIN LA), 50 MG JECTION, ISATUXIMAB-IRFC, 10 MG	J9204 J9205 J9206 J9207 J9208 J9209 J9210 J9211 J9214 J9215 J9217 J9218 J9223 J9225 J9226 J9227
JECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG JECTION, MOGAMULIZUMAB-KPKC, 1 MG JECTION, IRINOTECAN LIPOSOME, 1 MG JECTION, IRINOTECAN, 20 MG JECTION, IXABEPILONE, 1 MG JECTION, IFOSFAMIDE, 1 GRAM JECTION, MESNA, 200 MG JECTION, MESNA, 200 MG JECTION, EMAPALUMAB-LZSG, 1 MG JECTION, IDARUBICIN HYDROCHLORIDE, 5 MG JECTION, INTERFERON, ALFA-2B, RECOMBINANT, 1 MILLION UNITS JECTION, INTERFERON, ALFA-N3, (HUMAN LEUKOCYTE DERIVED), 250,000 IU UPROLIDE ACETATE (FOR DEPOT SUSPENSION), 7.5 MG UPROLIDE ACETATE, PER 1 MG JECTION, LURBINECTEDIN, 0.1 MG STRELIN IMPLANT (VANTAS), 50 MG STRELIN IMPLANT (SUPPRELIN LA), 50 MG JECTION, ISATUXIMAB-IRFC, 10 MG JECTION, IPILIMUMAB, 1 MG	J9204 J9205 J9206 J9207 J9208 J9209 J9210 J9211 J9214 J9215 J9217 J9218 J9223 J9225 J9226 J9227 J9228
IJECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG IJECTION, MOGAMULIZUMAB-KPKC, 1 MG IJECTION, IRINOTECAN LIPOSOME, 1 MG IJECTION, IRINOTECAN, 20 MG IJECTION, IRINOTECAN, 20 MG IJECTION, IXABEPILONE, 1 MG IJECTION, IFOSFAMIDE, 1 GRAM IJECTION, MESNA, 200 MG IJECTION, EMAPALUMAB-LZSG, 1 MG IJECTION, EMAPALUMAB-LZSG, 1 MG IJECTION, IDARUBICIN HYDROCHLORIDE, 5 MG IJECTION, INTERFERON, ALFA-2B, RECOMBINANT, 1 MILLION UNITS IJECTION, INTERFERON, ALFA-N3, (HUMAN LEUKOCYTE DERIVED), 250,000 IU EUPROLIDE ACETATE (FOR DEPOT SUSPENSION), 7.5 MG EUPROLIDE ACETATE, PER 1 MG IJECTION, LURBINECTEDIN, 0.1 MG STRELIN IMPLANT (VANTAS), 50 MG STRELIN IMPLANT (SUPPRELIN LA), 50 MG IJECTION, ISATUXIMAB-IRFC, 10 MG IJECTION, IPILIMUMAB, 1 MG IJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG	J9204 J9205 J9206 J9207 J9208 J9209 J9210 J9211 J9214 J9215 J9217 J9218 J9223 J9225 J9226 J9227
IJECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG IJECTION, MOGAMULIZUMAB-KPKC, 1 MG IJECTION, IRINOTECAN LIPOSOME, 1 MG IJECTION, IRINOTECAN, 20 MG IJECTION, IRINOTECAN, 20 MG IJECTION, IRINOTECAN, 20 MG IJECTION, IFOSFAMIDE, 1 GRAM IJECTION, IFOSFAMIDE, 1 GRAM IJECTION, MESNA, 200 MG IJECTION, EMAPALUMAB-LZSG, 1 MG IJECTION, EMAPALUMAB-LZSG, 1 MG IJECTION, INTERFERON, ALFA-2B, RECOMBINANT, 1 MILLION UNITS IJECTION, INTERFERON, ALFA-N3, (HUMAN LEUKOCYTE DERIVED), 250,000 IU IJECTION, INTERFERON, ALFA-N3, (HUMAN LEUKOCYTE DERIVED), 250,000 IU IJECTION, LURBINECTEDIN, 0.1 MG IJECTION, LURBINECTEDIN, 0.1 MG STRELIN IMPLANT (VANTAS), 50 MG STRELIN IMPLANT (SUPPRELIN LA), 50 MG IJECTION, ISATUXIMAB-IRFC, 10 MG IJECTION, IPILIMUMAB, 1 MG IJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG IJECTION, MECHLORETHAMINE HYDROCHLORIDE, (NITROGEN MUSTARD), 10 MG	J9204 J9205 J9206 J9207 J9208 J9209 J9210 J9211 J9214 J9215 J9217 J9218 J9223 J9225 J9226 J9227 J9228 J9229
OSERELIN ACETATE IMPLANT, PER 3.6 MG IJECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG IJECTION, MOGAMULIZUMAB-KPKC, 1 MG IJECTION, IRINOTECAN LIPOSOME, 1 MG IJECTION, IRINOTECAN, 20 MG IJECTION, IRINOTECAN, 20 MG IJECTION, IROSFAMIDE, 1 MG IJECTION, IFOSFAMIDE, 1 GRAM IJECTION, MESNA, 200 MG IJECTION, MESNA, 200 MG IJECTION, IDARUBICIN HYDROCHLORIDE, 5 MG IJECTION, INTERFERON, ALFA-2B, RECOMBINANT, 1 MILLION UNITS IJECTION, INTERFERON, ALFA-N3, (HUMAN LEUKOCYTE DERIVED), 250,000 IU EUPROLIDE ACETATE (FOR DEPOT SUSPENSION), 7.5 MG IJECTION, LURBINECTEDIN, 0.1 MG ISTRELIN IMPLANT (VANTAS), 50 MG ISTRELIN IMPLANT (VANTAS), 50 MG IJECTION, ISATUXIMAB-IRFC, 10 MG IJECTION, IPILIMUMAB, 1 MG IJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG IJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG IJECTION, MECHLORETHAMINE HYDROCHLORIDE, (NITROGEN MUSTARD), 10 MG IJECTION, MELPHALAN (EVOMELA), 1 MG	J9204 J9205 J9206 J9207 J9208 J9209 J9210 J9211 J9214 J9215 J9217 J9218 J9223 J9225 J9226 J9227 J9228 J9229 J9230
IJECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG IJECTION, MOGAMULIZUMAB-KPKC, 1 MG IJECTION, IRINOTECAN LIPOSOME, 1 MG IJECTION, IRINOTECAN, 20 MG IJECTION, IRINOTECAN, 20 MG IJECTION, IXABEPILONE, 1 MG IJECTION, IFOSFAMIDE, 1 GRAM IJECTION, IFOSFAMIDE, 1 GRAM IJECTION, MESNA, 200 MG IJECTION, EMAPALUMAB-LZSG, 1 MG IJECTION, IDARUBICIN HYDROCHLORIDE, 5 MG IJECTION, INTERFERON, ALFA-2B, RECOMBINANT, 1 MILLION UNITS IJECTION, INTERFERON, ALFA-N3, (HUMAN LEUKOCYTE DERIVED), 250,000 IU EUPROLIDE ACETATE (FOR DEPOT SUSPENSION), 7.5 MG EUPROLIDE ACETATE, PER 1 MG IJECTION, LURBINECTEDIN, 0.1 MG ISTRELIN IMPLANT (VANTAS), 50 MG ISTRELIN IMPLANT (VANTAS), 50 MG IJECTION, ISATUXIMAB-IRFC, 10 MG IJECTION, ISATUXIMAB, 1 MG IJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG IJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG IJECTION, MECHLORETHAMINE HYDROCHLORIDE, (NITROGEN MUSTARD), 10 MG IJECTION, MELPHALAN HYDROCHLORIDE, 50 MG IJECTION, MELPHALAN (EVOMELA), 1 MG IJECTION, MELPHALAN FLUFENAMIDE, 1 MG	J9204 J9205 J9206 J9207 J9208 J9209 J9210 J9211 J9214 J9215 J9217 J9218 J9223 J9225 J9226 J9227 J9228 J9229 J9230 J9245 J9246 J9247
JECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG JECTION, MOGAMULIZUMAB-KPKC, 1 MG JECTION, IRINOTECAN LIPOSOME, 1 MG JECTION, IRINOTECAN, 20 MG JECTION, IRINOTECAN, 20 MG JECTION, IXABEPILONE, 1 MG JECTION, IFOSFAMIDE, 1 GRAM JECTION, IFOSFAMIDE, 1 GRAM JECTION, MESNA, 200 MG JECTION, MESNA, 200 MG JECTION, IDARUBICIN HYDROCHLORIDE, 5 MG JECTION, INTERFERON, ALFA-2B, RECOMBINANT, 1 MILLION UNITS JECTION, INTERFERON, ALFA-N3, (HUMAN LEUKOCYTE DERIVED), 250,000 IU FUPROLIDE ACETATE (FOR DEPOT SUSPENSION), 7.5 MG FUPROLIDE ACETATE, PER 1 MG JECTION, LURBINECTEDIN, 0.1 MG STRELIN IMPLANT (VANTAS), 50 MG STRELIN IMPLANT (VANTAS), 50 MG JECTION, ISATUXIMAB-IRFC, 10 MG JECTION, IPILIMUMAB, 1 MG JECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG JECTION, MECHLORETHAMINE HYDROCHLORIDE, (NITROGEN MUSTARD), 10 MG JECTION, MELPHALAN HYDROCHLORIDE, 50 MG JECTION, MELPHALAN (EVOMELA), 1 MG	J9204 J9205 J9206 J9207 J9208 J9209 J9210 J9211 J9214 J9215 J9217 J9218 J9223 J9225 J9226 J9227 J9228 J9229 J9230 J9245 J9246

HCPCS (cont)	
METHOTREXATE SODIUM, 50 MG	J9260
INJECTION, NELARABINE, 50 MG	J9261
INJECTION, OMACETAXINE MEPESUCCINATE, 0.01 MG	J9262
INJECTION, OXALIPLATIN, 0.5 MG	J9263
INJECTION, PACLITAXEL PROTEIN-BOUND PARTICLES, 1 MG	J9264
INJECTION, PEGASPARGASE, PER SINGLE DOSE VIAL	J9266
INJECTION, PACLITAXEL, 1 MG	J9267
INJECTION, PENTOSTATIN, 10 MG INJECTION, TAGRAXOFUSP-ERZS, 10 MCG	Ј9268 Ј9269
INJECTION, PEMBROLIZUMAB, 1 MG	J9271
INJECTION, DOSTARLIMAB-GXLY, 10 MG	J9272
INJECTION, TISOTUMAB VEDOTIN-TFTV, 1 MG	J9273
INJECTION, TEBENTAFUSP-TEBN, 1 MICROGRAM	J9274
INJECTION, MITOMYCIN, 5 MG	J9280
MITOMYCIN PYELOCALYCEAL INSTILLATION, 1 MG	J9281
INJECTION, OLARATUMAB, 10 MG	J9285
INJECTION, MITOXANTRONE HYDROCHLORIDE, PER 5 MG	J9293
Injection, pemetrexed (hospira) not therapeutically equivalent to j9305, 10 mg INJECTION, NECITUMUMAB, 1 MG	J9294 J9295
Injection, pemetrexed (accord) not therapeutically equivalent to j9305, 10 mg	J9296
Injection, pemetrexed (accord) not therapeutically equivalent to j9305, 10 mg	J9297
INJECTION, NIVOLUMAB AND RELATLIMAB-RMBW, 3 MG/1 MG	J9298
INJECTION, NIVOLUMAB, 1 MG	J9299
INJECTION, OBINUTUZUMAB, 10 MG	J9301
INJECTION, OFATUMUMAB, 10 MG	J9302
INJECTION, PANITUMUMAB, 10 MG	J9303
INJECTION, PEMETREXED (PEMFEXY), 10 MG	J9304
INJECTION, PEMETREXED, 10 MG	J9305
INJECTION, PERTUZUMAB, 1 MG	J9306
INJECTION, PRALATREXATE, 1 MG INJECTION, RAMUCIRUMAB, 5 MG	J9307 J9308
INJECTION, POLATUZUMAB VEDOTIN-PIIQ, 1 MG	J9309
INJECTION, POLATOZOMAD VEDOTIN-FING, FIMO	J9311
INJECTION, RITUXIMAB, 10 MG	J9312
INJECTION, MOXETUMOMAB PASUDOTOX-TDFK, 0.01 MG	J9313
Injection, pemetrexed (teva) not therapeutically equivalent to j9305, 10 mg	J9314
INJECTION, PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF, PER 10 MF	J9316
INJECTION, SACITUZUMAB GOVITECAN-HZIY, 2.5 MG	J9317
INJECTION, ROMIDEPSIN, NON-LYOPHILIZED, 0.1 MG	J9318
INJECTION, ROMIDEPSIN, LYOPHILIZED, 0.1 MG	J9319
	10220
INJECTION, STREPTOZOCIN, 1 GRAM	J9320
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg	J9322
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed ditromethamine, 10 mg	Ј9322 Ј9323
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed ditromethamine, 10 mg INJECTION, TALIMOGENE LAHERPAREPVEC, 1 MILLION PLAQUE FORMING UNITS (PFU)	Ј9322 Ј9323 Ј9325
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed ditromethamine, 10 mg	Ј9322 Ј9323
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed diffromethamine, 10 mg INJECTION, TALIMOGENE LAHERPAREPVEC, 1 MILLION PLAQUE FORMING UNITS (PFU) INJECTION, TEMOZOLOMIDE, 1 MG	J9322 J9323 J9325 J9328
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed ditromethamine, 10 mg INJECTION, TALIMOGENE LAHERPAREPVEC, 1 MILLION PLAQUE FORMING UNITS (PFU) INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, TEMSIROLIMUS, 1 MG INJECTION, SIROLIMUS PROTEIN-BOUND PARTICLES, 1 MG INJECTION, THIOTEPA, 15 MG	J9322 J9323 J9325 J9328 J9330
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed ditromethamine, 10 mg INJECTION, TALIMOGENE LAHERPAREPVEC, 1 MILLION PLAQUE FORMING UNITS (PFU) INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, TEMSIROLIMUS, 1 MG INJECTION, SIROLIMUS PROTEIN-BOUND PARTICLES, 1 MG INJECTION, THIOTEPA, 15 MG Indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel	J9322 J9323 J9325 J9328 J9330 J9331 J9340
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed ditromethamine, 10 mg INJECTION, TALIMOGENE LAHERPAREPVEC, 1 MILLION PLAQUE FORMING UNITS (PFU) INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, TEMSIROLIMUS, 1 MG INJECTION, SIROLIMUS PROTEIN-BOUND PARTICLES, 1 MG INJECTION, THIOTEPA, 15 MG Indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).	J9322 J9323 J9325 J9328 J9330 J9331 J9340
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed ditromethamine, 10 mg INJECTION, TALIMOGENE LAHERPAREPVEC, 1 MILLION PLAQUE FORMING UNITS (PFU) INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, TEMSIROLIMUS, 1 MG INJECTION, SIROLIMUS PROTEIN-BOUND PARTICLES, 1 MG INJECTION, THIOTEPA, 15 MG Indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). Injection, tremelimumab-actl, 1 mg	J9322 J9323 J9325 J9328 J9330 J9331 J9340 J9345
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed ditromethamine, 10 mg INJECTION, TALIMOGENE LAHERPAREPVEC, 1 MILLION PLAQUE FORMING UNITS (PFU) INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, TEMSIROLIMUS, 1 MG INJECTION, SIROLIMUS PROTEIN-BOUND PARTICLES, 1 MG INJECTION, THIOTEPA, 15 MG Indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). Injection, tremelimumab-actl, 1 mg INJECTION, NAXITAMAB-GQGK, 1 MG	J9322 J9323 J9325 J9328 J9330 J9331 J9340 J9345 J9347 J9348
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed ditromethamine, 10 mg INJECTION, TALIMOGENE LAHERPAREPVEC, 1 MILLION PLAQUE FORMING UNITS (PFU) INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, TEMSIROLIMUS, 1 MG INJECTION, SIROLIMUS PROTEIN-BOUND PARTICLES, 1 MG INJECTION, THIOTEPA, 15 MG Indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). Injection, tremelimumab-actl, 1 mg INJECTION, NAXITAMAB-GQGK, 1 MG INJECTION, TAFASITAMAB-CXIX, 2 MG	J9322 J9323 J9325 J9328 J9330 J9331 J9340 J9345 J9347 J9348 J9349
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed ditromethamine, 10 mg INJECTION, TALIMOGENE LAHERPAREPVEC, 1 MILLION PLAQUE FORMING UNITS (PFU) INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, TEMSIROLIMUS, 1 MG INJECTION, SIROLIMUS PROTEIN-BOUND PARTICLES, 1 MG INJECTION, THIOTEPA, 15 MG Indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). Injection, tremelimumab-actl, 1 mg INJECTION, NAXITAMAB-GQGK, 1 MG INJECTION, TAFASITAMAB-CXIX, 2 MG Injection, mosunetuzumab-axgb, 1 mg	J9322 J9323 J9325 J9328 J9330 J9331 J9340 J9345 J9347 J9348 J9349 J9350
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed ditromethamine, 10 mg INJECTION, TALIMOGENE LAHERPAREPVEC, 1 MILLION PLAQUE FORMING UNITS (PFU) INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, TEMSIROLIMUS, 1 MG INJECTION, SIROLIMUS PROTEIN-BOUND PARTICLES, 1 MG INJECTION, THIOTEPA, 15 MG Indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). Injection, tremelimumab-actl, 1 mg INJECTION, NAXITAMAB-GQGK, 1 MG INJECTION, TAFASITAMAB-CXIX, 2 MG	J9322 J9323 J9325 J9328 J9330 J9331 J9340 J9345 J9347 J9348 J9349
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed ditromethamine, 10 mg INJECTION, TALIMOGENE LAHERPAREPVEC, 1 MILLION PLAQUE FORMING UNITS (PFU) INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, TEMSIROLIMUS, 1 MG INJECTION, SIROLIMUS PROTEIN-BOUND PARTICLES, 1 MG INJECTION, THIOTEPA, 15 MG Indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). Injection, tremelimumab-actl, 1 mg INJECTION, NAXITAMAB-GQGK, 1 MG INJECTION, TAFASITAMAB-CXIX, 2 MG Injection, mosunetuzumab-axgb, 1 mg INJECTION, TOPOTECAN, 0.1 MG	J9322 J9323 J9325 J9328 J9330 J9331 J9340 J9345 J9347 J9348 J9349 J9350 J9351
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed ditromethamine, 10 mg INJECTION, TALIMOGENE LAHERPAREPVEC, 1 MILLION PLAQUE FORMING UNITS (PFU) INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, SIROLIMUS, 1 MG INJECTION, SIROLIMUS PROTEIN-BOUND PARTICLES, 1 MG INJECTION, THIOTEPA, 15 MG Indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). Injection, tremelimumab-actl, 1 mg INJECTION, NAXITAMAB-GQGK, 1 MG INJECTION, TAFASITAMAB-CXIX, 2 MG Injection, mosunetuzumab-axgb, 1 mg INJECTION, TOPOTECAN, 0.1 MG INJECTION, TRABECTEDIN, 0.1 MG INJECTION, MARGETUXIMAB-CMKB, 5 MG INJECTION, ADO-TRASTUZUMAB EMTANSINE, 1 MG	J9322 J9323 J9325 J9328 J9330 J9331 J9340 J9345 J9347 J9348 J9349 J9350 J9351 J9352 J9353 J9354
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed ditromethamine, 10 mg INJECTION, TALIMOGENE LAHERPAREPVEC, 1 MILLION PLAQUE FORMING UNITS (PFU) INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, TEMSIROLIMUS, 1 MG INJECTION, SIROLIMUS PROTEIN-BOUND PARTICLES, 1 MG INJECTION, THIOTEPA, 15 MG Indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). Injection, tremelimumab-actl, 1 mg INJECTION, NAXITAMAB-GQGK, 1 MG INJECTION, TAFASITAMAB-CXIX, 2 MG Injection, mosunetuzumab-axgb, 1 mg INJECTION, TOPOTECAN, 0.1 MG INJECTION, TRABECTEDIN, 0.1 MG INJECTION, MARGETUXIMAB-CMKB, 5 MG INJECTION, ADO-TRASTUZUMAB EMTANSINE, 1 MG INJECTION, TRASTUZUMAB, EXCLUDES BIOSIMILAR, 10 MG	J9322 J9323 J9325 J9328 J9330 J9331 J9340 J9345 J9347 J9348 J9349 J9350 J9351 J9352 J9353 J9354 J9355
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed ditromethamine, 10 mg INJECTION, TALIMOGENE LAHERPAREPVEC, 1 MILLION PLAQUE FORMING UNITS (PFU) INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, TEMSIROLIMUS, 1 MG INJECTION, SIROLIMUS PROTEIN-BOUND PARTICLES, 1 MG INJECTION, THIOTEPA, 15 MG Indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). Injection, tremelimumab-actl, 1 mg INJECTION, NAXITAMAB-GQGK, 1 MG INJECTION, TAFASITAMAB-CXIX, 2 MG Injection, mosunetuzumab-axgb, 1 mg INJECTION, TOPOTECAN, 0.1 MG INJECTION, TRABECTEDIN, 0.1 MG INJECTION, MARGETUXIMAB-CMKB, 5 MG INJECTION, ADO-TRASTUZUMAB EMTANSINE, 1 MG INJECTION, TRASTUZUMAB, EXCLUDES BIOSIMILAR, 10 MG INJECTION, TRASTUZUMAB, 10 MG AND HYALURONIDASE-OYSK	J9322 J9323 J9325 J9328 J9330 J9331 J9340 J9345 J9347 J9348 J9349 J9350 J9351 J9352 J9353 J9354 J9355 J9356
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed ditromethamine, 10 mg INJECTION, TALIMOGENE LAHERPAREPVEC, 1 MILLION PLAQUE FORMING UNITS (PFU) INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, TEMSIROLIMUS, 1 MG INJECTION, SIROLIMUS PROTEIN-BOUND PARTICLES, 1 MG INJECTION, THIOTEPA, 15 MG Indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). Injection, tremelimumab-actl, 1 mg INJECTION, NAXITAMAB-GQGK, 1 MG INJECTION, TAFASITAMAB-CXIX, 2 MG Injection, mosunetuzumab-axgb, 1 mg INJECTION, TOPOTECAN, 0.1 MG INJECTION, TRABECTEDIN, 0.1 MG INJECTION, MARGETUXIMAB-CMKB, 5 MG INJECTION, ADO-TRASTUZUMAB EMTANSINE, 1 MG INJECTION, TRASTUZUMAB, 10 MG AND HYALURONIDASE-OYSK INJECTION, VALRUBICIN, INTRAVESICAL, 200 MG	J9322 J9323 J9325 J9328 J9330 J9331 J9340 J9345 J9347 J9348 J9349 J9350 J9351 J9352 J9353 J9354 J9355 J9356 J9357
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed ditromethamine, 10 mg INJECTION, TALIMOGENE LAHERPAREPVEC, 1 MILLION PLAQUE FORMING UNITS (PFU) INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, SIROLIMUS PROTEIN-BOUND PARTICLES, 1 MG INJECTION, THIOTEPA, 15 MG INJECTION, THIOTEPA, 15 MG Indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). Injection, tremelimumab-actl, 1 mg INJECTION, NAXITAMAB-GQGK, 1 MG INJECTION, TAFASITAMAB-CXIX, 2 MG Injection, mosunetuzumab-axgb, 1 mg INJECTION, TOPOTECAN, 0.1 MG INJECTION, TRABECTEDIN, 0.1 MG INJECTION, MARGETUZIMAB-CMKB, 5 MG INJECTION, MARGETUZIMAB EMTANSINE, 1 MG INJECTION, TRASTUZUMAB, EXCLUDES BIOSIMILAR, 10 MG INJECTION, TRASTUZUMAB, 10 MG AND HYALURONIDASE-OYSK INJECTION, VALRUBICIN, INTRAVESICAL, 200 MG INJECTION, FAM-TRASTUZUMAB DERUXTECAN-NXKI, 1 MG	J9322 J9323 J9325 J9328 J9330 J9331 J9340 J9345 J9347 J9348 J9349 J9350 J9351 J9352 J9353 J9354 J9355 J9356 J9357 J9358
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed difformethamine, 10 mg INJECTION, TALIMOGENE LAHERPAREPVEC, 1 MILLION PLAQUE FORMING UNITS (PFU) INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, SIROLIMUS, 1 MG INJECTION, SIROLIMUS PROTEIN-BOUND PARTICLES, 1 MG INJECTION, THIOTEPA, 15 MG Indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). Injection, tremelimumab-actl, 1 mg INJECTION, NAXITAMAB-GQGK, 1 MG INJECTION, TAFASITAMAB-CXIX, 2 MG Injection, mosunetuzumab-axgb, 1 mg INJECTION, TOPOTECAN, 0.1 MG INJECTION, TRABECTEDIN, 0.1 MG INJECTION, MARGETUXIMAB-CMKB, 5 MG INJECTION, ADO-TRASTUZUMAB EMTANSINE, 1 MG INJECTION, TRASTUZUMAB, 10 MG AND HYALURONIDASE-OYSK INJECTION, VALRUBICIN, INTRAVESICAL, 200 MG INJECTION, FAM-TRASTUZUMAB DERUXTECAN-NXKI, 1 MG INJECTION, LONCASTUXIMAB TESIRINE-LPYL, 0.075 MG	J9322 J9323 J9325 J9328 J9330 J9331 J9340 J9345 J9347 J9348 J9349 J9350 J9351 J9352 J9353 J9354 J9355 J9356 J9357 J9358 J9359
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed ditromethamine, 10 mg INJECTION, TALIMOGENE LAHERPAREPVEC, 1 MILLION PLAQUE FORMING UNITS (PFU) INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, SIROLIMUS, 1 MG INJECTION, SIROLIMUS PROTEIN-BOUND PARTICLES, 1 MG INJECTION, THIOTEPA, 15 MG Indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). Injection, tremelimumab-actl, 1 mg INJECTION, NAXITAMAB-GQGK, 1 MG INJECTION, TAFASITAMAB-CXIX, 2 MG Injection, mosunetuzumab-axgb, 1 mg INJECTION, TOPOTECAN, 0.1 MG INJECTION, TRABECTEDIN, 0.1 MG INJECTION, TRASTUZUMAB EMTANSINE, 1 MG INJECTION, TRASTUZUMAB, EXCLUDES BIOSIMILAR, 10 MG INJECTION, TRASTUZUMAB, 10 MG AND HYALURONIDASE-OYSK INJECTION, VALRUBICIN, INTRAVESICAL, 200 MG INJECTION, FAM-TRASTUZUMAB DERUXTECAN-NXKI, 1 MG INJECTION, LONCASTUXIMAB TESIRINE-LPYL, 0.075 MG INJECTION, VINBLASTINE SULFATE, 1 MG	J9322 J9323 J9325 J9328 J9330 J9331 J9340 J9345 J9347 J9348 J9349 J9350 J9351 J9352 J9353 J9354 J9355 J9356 J9357 J9358 J9359 J9360
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed ditromethamine, 10 mg INJECTION, TALIMOGENE LAHERPAREPYEC, 1 MILLION PLAQUE FORMING UNITS (PFU) INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, SIROLIMUS, 1 MG INJECTION, SIROLIMUS PROTEIN-BOUND PARTICLES, 1 MG INJECTION, THIOTEPA, 15 MG Indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). Injection, tremelimumab-actl, 1 mg INJECTION, NAXITAMAB-GQGK, 1 MG INJECTION, TAFASITAMAB-CXIX, 2 MG Injection, mosunetuzumab-axgb, 1 mg INJECTION, TRABECTEDIN, 0.1 MG INJECTION, TRABECTEDIN, 0.1 MG INJECTION, MARGETUXIMAB-CMKB, 5 MG INJECTION, ADO-TRASTUZUMAB EMTANSINE, 1 MG INJECTION, TRASTUZUMAB, EXCLUDES BIOSIMILAR, 10 MG INJECTION, TRASTUZUMAB, EXCLUDES BIOSIMILAR, 10 MG INJECTION, VALRUBICIN, INTRAVESICAL, 200 MG INJECTION, FAM-TRASTUZUMAB DERUXTECAN-NXKI, 1 MG INJECTION, LONCASTUXIMAB TESIRINE-LPYL, 0.075 MG INJECTION, VINBLASTINE SULFATE, 1 MG VINCRISTINE SULFATE, 1 MG	J9322 J9323 J9325 J9328 J9330 J9331 J9340 J9345 J9347 J9348 J9349 J9350 J9351 J9352 J9353 J9354 J9355 J9356 J9357 J9358 J9359 J9360 J9370
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed diffromethamine, 10 mg INJECTION, TALIMOGENE LAHERPAREPVEC, 1 MILLION PLAQUE FORMING UNITS (PFU) INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, TEMSIROLIMUS, 1 MG INJECTION, SIROLIMUS PROTEIN-BOUND PARTICLES, 1 MG INJECTION, SIROLIMUS PROTEIN-BOUND PARTICLES, 1 MG INJECTION, THIOTEPA, 15 MG INGLICATE OF the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). Injection, tremelimumab-actl, 1 mg INJECTION, NAXITAMAB-GQGK, 1 MG INJECTION, TAFASITAMAB-CXIX, 2 MG Injection, mosunetuzumab-axgb, 1 mg INJECTION, TAFASITAMAB-CXIX, 2 MG INJECTION, TRABECTEDIN, 0.1 MG INJECTION, TRABECTEDIN, 0.1 MG INJECTION, MARGETUXIMAB-CMKB, 5 MG INJECTION, MARGETUXIMAB EMTANSINE, 1 MG INJECTION, TRASTUZUMAB, EXCLUDES BIOSIMILAR, 10 MG INJECTION, TRASTUZUMAB, EXCLUDES BIOSIMILAR, 10 MG INJECTION, VALRUBICIN, INTRAVESICAL, 200 MG INJECTION, VALRUBICIN, INTRAVESICAL, 200 MG INJECTION, LONCASTUXIMAB TESIRINE-LPYL, 0.075 MG INJECTION, VINBLASTINE SULFATE, 1 MG INJECTION, VINCRISTINE SULFATE, 1 MG INJECTION, VINCRISTINE SULFATE, 1 MG INJECTION, VINCRISTINE SULFATE LIPOSOME, 1 MG	J9322 J9323 J9325 J9328 J9330 J9331 J9340 J9345 J9347 J9348 J9349 J9350 J9351 J9352 J9353 J9354 J9355 J9356 J9357 J9358 J9359 J9360 J9370
INJECTION, STREPTOZOCIN, 1 GRAM Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed ditromethamine, 10 mg INJECTION, TALIMOGENE LAHERPAREPVEC, 1 MILLION PLAQUE FORMING UNITS (PFU) INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, TEMOZOLOMIDE, 1 MG INJECTION, SIROLIMUS, 1 MG INJECTION, SIROLIMUS PROTEIN-BOUND PARTICLES, 1 MG INJECTION, THIOTEPA, 15 MG Indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). Injection, tremelimumab-actl, 1 mg INJECTION, NAXITAMAB-GQGK, 1 MG INJECTION, TAFASITAMAB-CXIX, 2 MG Injection, mosunetuzumab-axgb, 1 mg INJECTION, TRABECTEDIN, 0.1 MG INJECTION, TRABECTEDIN, 0.1 MG INJECTION, MARGETUXIMAB-CMKB, 5 MG INJECTION, ADO-TRASTUZUMAB EMTANSINE, 1 MG INJECTION, TRASTUZUMAB, EXCLUDES BIOSIMILAR, 10 MG INJECTION, TRASTUZUMAB, EXCLUDES BIOSIMILAR, 10 MG INJECTION, VALRUBICIN, INTRAVESICAL, 200 MG INJECTION, FAM-TRASTUZUMAB DERUXTECAN-NXKI, 1 MG INJECTION, LONCASTUXIMAB TESIRINE-LPYL, 0.075 MG INJECTION, VINBLASTINE SULFATE, 1 MG VINCRISTINE SULFATE, 1 MG	J9322 J9323 J9325 J9328 J9330 J9331 J9340 J9345 J9347 J9348 J9349 J9350 J9351 J9352 J9353 J9354 J9355 J9356 J9357 J9358 J9359 J9360 J9370

Injection, Livestrant (leva) not therapeutically equivalent to J9395, 25 mg J9393 Injection, Livestrant (fesenius kabi) not therapeutically equivalent to J9395, 25 mg J9394 Injection, Livestrant (fesenius kabi) not therapeutically equivalent to J9395, 25 mg J9395 INJECTION, PLOYENTRANT, 25 MG J9305 INJECTION, PORTIMER SODIUM, 75 MG J9400 INJECTION, PORTIMER SODIUM, 75 MG J9400 INJECTION, PORTIMER SODIUM, 75 MG J9400 INJECTION, PORTIMER SODIUM, 75 MG J9500 NOT OTHERWISE CLASSIFIED, ANTINEOPLASTIC DRUGS J9999 INJECTION, TEINPOSIDE, 50 MG Q2017 ANICABRAÇENE CILOLEUCEL, UP TO 200 MILLION AUTOLOGOUS ANTI-CDI9 CART CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER INFUSION Q2041 INJECTION, DEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER INFUSION Q2042 AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE SPILLEUCELT, INNIMUM OF 50 MILLION AUTOLOGOUS CD54+ CELLS ACTIVATED WITH PAP-GM-CSF, INCLUDING LEUKAPHERESIS AND ALL OTHER REPARATIONEY PROCEDURES, PER INFUSION INJECTION, DOXORUBICION HYDROCHLORIDE, UPOSOMAL, IMPORTED UPODOX, 10 MG Q2049 INJECTION, DOXORUBICION HYDROCHLORIDE, UPOSOMAL, IMPORTED UPODOX, 10 MG Q2050 INJECTION, DOXORUBICION HYDROCHLORIDE, UPOSOMAL, INFORMENT SEPECIFIED, 10MG Q2050 INJECTION, DOXORUBICION HYDROCHLORIDE, UPOSOMAL, INFORMENT SEPECIFIED, 10MG Q2050 INJECTION, DOXORUBICION HYDROCHLORIDE, UPOSOMAL, INFORMENT SEPECIFIED, 10MG Q2050 INJECTION, DOXORUBICION HYDROCHLORIDE, UPOSOMAL INFORMENT SEPECIFIED, 10MG Q2051 INJECTION, DOXORUBICION HYDROCHLORIDE, UPOSOMAL MORDINA SEPECIFIED, 10MG Q2051 INJECTION, DEVACIZUMAP HYDROCHLORIDE, UPOSOMAL MYDROCHLORIDE, UPOSOMAL MYDROCHLOR	HCDCS (conf)	
Injection, full-vestrant (fresenius kabl.) not therapeutically equivalent to J9395. 25 mg J9395 INJECTION, PULV-STEANT, 25 MG J9400 INJECTION, PULV-STEANT, 25 MG J9400 INJECTION, PORFIMER SODIUM, 75 MG J9400 INJECTION, PORFIMER SODIUM, 75 MG J9600 INJECTION, PORFIMER SODIUM, 75 MG J9600 INJECTION, PORFIMER SODIUM, 75 MG J9799 INJECTION, TENIPOSIDE, 50 MG Q2017 INJECTION, TENIPOSIDE, 50 MG Q2018 INJECTION, DEVELOPMENT OF A MILLION AUTOLOGOUS ANTI-CD19 CAR T CELLS, Q2041 INJECTION, DOSE PREPARATION PROCEDURES, PER INFESION Q2042 INJECTION, DOSE PREPARATION PROCEDURES, PER INFESION Q2043 INJECTION, DOXORUBICIN HYDROCHIORIDE, LIPOSOMAL, IMPORTED LIPODOX, 10 MG Q2049 INJECTION, DOXORUBICIN HYDROCHIORIDE, LIPOSOMAL, INFORTED LIPODOX, 10 MG Q2049 INJECTION, DOXORUBICIN HYDROCHIORIDE, LIPOSOMAL, INTO THERMES SPECIFIED, 10MG Q2050 INJECTION, DOXORUBICIN HYDROCHIORIDE, LIPOSOMAL, INTO THERMES SPECIFIED, 10MG Q2050 INJECTION, DOXORUBICIN HYDROCHIORIDE, LIPOSOMAL, INTO THERMES SPECIFIED, 10MG Q2050 INJECTION, DOXORUBICIN HYDROCHIORIDE, LIPOSOMAL, INTO THERMES SPECIFIED, 10MG Q2050 INJECTION, DOXORUBICIN HYDROCHIORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10MG Q2050 INJECTION, DOXORUBICIN HYDROCHIORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10MG Q2050 INJECTION, DOXORUBICIN HYDROCHIORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10MG Q2050 INJECTION, DEVALUATION OF THE TOT TO THE THERMES STEAD Q2054 LISOCABTAGENE MARALEUCEL, UP TO 110 MILLION AUTOLOGOUS ANTI-CD19 CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE AUTOLEUCEL, UP TO 10M MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2056 CILTACABTAGENE AUTOLEUCEL, UP TO 10M MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BC	HCPCS (cont) Injection, fullyestrant (teva) not the rapeutically equivalent to 19395, 25 mg.	19393
INJECTION, PULYESTRANT, 25 MG INJECTION, IVA-REIBRECPET, I MG INJECTION, VAPABRERCEPT, I MG INJECTION, PORFIMER SODIUM, 75 MG INJECTION, PERILOPOSIDE, 30 MG Q2017 AXICABTAGENE CILOLEUCEL, UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR T CELLS, INCLIUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER INFUSION INSAGENIECLEUCEL, UP TO 400 MILLION CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE SIPULEUCEL-T, MINIMUM OF 50 MILLION AUTOLOGOUS CD54+ CELLS ACTIVATED WITH PAP-GM-CSF, INCLUDING LEUKAPHERESIS AND ALI OTHER PREPARATORY PROCEDURES, PER INFUSION INJECTION, DOXORUBIGH HYDROCHLORIDE, UPOSOMAL, IMPORTED UPDOX. 10 MG Q2049 INJECTION, DOXORUBIGH HYDROCHLORIDE, UPOSOMAL, IMPORTED UPDOX. 10 MG Q2049 INJECTION, DOXORUBIGH HYDROCHLORIDE, UPOSOMAL, INFORTED UPDOX. 10 MG Q2050 BREXUCABTAGENE AUTOLEUCEL, UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE VICLEUCEL, UP TO 110 MILLION AUTOLOGOUS ANTI-CD19 CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE VICLEUCEL, UP TO 460 MILLION AUTOLOGOUS ANTI-CD19 CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE VICLEUCEL, UP TO 10 MILLION AUTOLOGOUS S-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2055 PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE AUTOLEUCEL, UP TO 10 MILLION AUTOLOGOUS S-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2056 PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE AUTOLEUCEL, UP TO 10 MILLION AUTOLOGOUS S-CELL MATURATION ANTIGEN (BCMA) DIRECTION, PEGFLIGRASTIM		
INJECTION, DEPRIMER SODIUM, 75 MG INJECTION, TENPOSIDE, 30 MG INJECTION, TENPOSIDE, 30 MG INJECTION, TENPOSIDE, 30 MG INJECTION, DEPRIMERESIS AND DOSE PREPARATION PROCEDURES, PER INFUSION INJECTION, DOSE PREPARATION PROCEDURES, PER INFUSION INJECTION, DOS MILLION CARP-POSITIVE YUBBLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE INJUEUR LEUKAPHERESIS AND ALL OTHER PREPARATIOR PROCEDURES, PER INFUSION INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, IMPORTED LIPODOX, 10 MG INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, INPORTED LIPODOX, 10 MG INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, INFORTED LIPODOX, 10 MG INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, INFORTED LIPODOX, 10 MG INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG INJECTION, ELIKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE INJECTION, ELIKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE INJECTION, ELIKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE INJECTION, ELIKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE INJECTION, ELIKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE INJECTION, ELIKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE INJECTION, ELIKAPHER		
INJECTION, PORFIMER SODIUM, 75 MG J9999 INJECTION, TENIPOSIDE, 50 MG AXICABIAGENE CILOSITED, ANTINEOPLASTIC DRUGS J9999 INJECTION, TENIPOSIDE, 50 MG AXICABIAGENE CILOLEUCEL, UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER INFUSION TISAGENLECLEUCEL, UP TO 400 MILLION AUTOLOGOUS ANTI-CD19 CAR T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER INFUSION TISAGENLECLEUCEL, UP TO 400 MILLION AUTOLOGOUS COSTA CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE SIPULEUCEL-T, MINIMUM OF 50 MILLION AUTOLOGOUS CD54+ CELLS ACTIVATED WITH PAP-GM-CSF, INCLUDING, LEUKAPHERESIS AND ALL OTHER PREPARATORY PROCEDURES, PER INFUSION INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, IMPORTED LIPODOX, 10 MG Q2049 INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, INTO OTHERWISE SPECIFIED, 10MG Q2050 BREXUCABTAGENE AUTOLEUCEL, UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE WICLEUCEL, UP TO 1110 MILLION AUTOLOGOUS ANTI-CD19 CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE VICLEUCEL, UP TO 460 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2055 PROCEDURES, PER THERAPEUTIC DOSE LITACABTAGENE AUTOLECLE, UP TO 100 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2056 PROCEDURES, PER THERAPEUTIC DOSE LITACABTAGENE AUTOLECL UP TO 100 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2056 PROCEDURES, PER THERAPEUTIC DOSE LITACABTAGENER AUTOLECL UP TO 100 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION		
NOT OTHERWISE CLASSIFIED, ANTINEOPLASTIC DRUGS J9999 NUSCTION, TENIPOSIDE, 50 MG AXICABTAGENE CILCLEUCEL, UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER INFUSION TRAGENIECIECUEL, UP TO 600 MILLION CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE SIPULEUCELT, MINIMUM OF 50 MILLION AUTOLOGOUS CD54+ CELLS, ACTIVATED WITH PAP-GM-CSF, INCLUDING LEUKAPHERESIS AND ALL OTHER PREPARATORY PROCEDURES, PER INFUSION INJECTION, DOXORDIBICIN HYDROCHLORIDE, LIPOSOMAL, IMPORTED LIPODOX, 10 MG Q2049 INJECTION, DOXORDIBICIN HYDROCHLORIDE, LIPOSOMAL, MIPORTED LIPODOX, 10 MG Q2050 BREXUCABTAGENE AUTOLEUCEL, UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE MARALEUCEL, UP TO 110 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE WICLEUCEL, UP TO 460 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T Q2054 LISOCABTAGENE WICLEUCEL, UP TO 100 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T Q2054 LISOCABTAGENE WICLEUCEL, UP TO 100 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T Q2054 LIBECABTAGENE WICLEUCEL, UP TO 100 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T Q2054 LIBECABTAGENE AUTOLEUCEL, UP TO 100 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T Q2055 PROCEDURES, PER THERAPEUTIC DOSE CILTACABTAGENE AUTOLEUCEL, UP TO 100 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2056 PROCEDURES, PER THERAPEUTIC DOSE CILTACABTAGENE AUTOLEUCEL, UP TO 100 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN INJECTION, BEVACIZUMAB-AWAB, BIOSIMILAR, INCROGRAM Q5101 INJECTION, BEVACIZUMAB-AWAB, BIOSIMILAR, (RAVASI), 10 MG Q5110 INJECTION, RESTUZUMAB-DATA, BIOSIMILAR, (RIVESTYM), 1 MICROGRAM Q5110 INJECTION, RASTU		J9600
INJECTION, TENIPOSIDE, 59 MG AXICABTAGENE CILOLEUCEL, UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER INFUSION TISAGENLECLEUCEL, UP TO 600 MILLION CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER ITHERAPEUTIC DOSE SPULEUCEL-T, MINIMUM OF 50 MILLION AUTOLOGOUS CD54+ CELLS ACTIVATED WITH PAP-GM-CSF, INCLUDING LEUKAPHERESIS AND ALL OTHER PREPARATORY PROCEDURES, PER INFUSION INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, IMPORTED LIPODOX, 10 MG G2049 INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, IMPORTED LIPODOX, 10 MG G2050 BREXUCABTAGENE AUTOLEUCEL, UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE MARALEUCEL, UP TO 110 MILLION AUTOLOGOUS ANTI-CD19 CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE WICLEUCEL, UP TO 460 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE AUTOLEUCEL, UP TO 100 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2055 PROCEDURES, PER THERAPEUTIC DOSE INJECTION, ELGRASTIM (G-CSF), BIOSIMILAR, (INTENDENCE) INJECTION, EPOEITIN ATTA-BIOSIMILAR, (RETACRIT) (FOR NON-ESRD USE), 1000 UNITS Q5101 INJECTION, EPOEITIN ATTA-BIOSIMILAR, (RETACRIT) (FOR NON-ESRD USE), 1000 UNITS Q5106 INJECTION, EPOEITIN ATTA-BIOSIMILAR, (INTENDENCE), 10 MG Q5111 INJECTION, TRASTUZUMAB-AWWB, BIOSIMILAR, (INVESTYM), 1 MGCOGRAM Q5111 INJECTION, TRASTUZUMAB-PURB, BIOSIMILAR, (INTENDENCE), 10 MG Q5111 INJECTION, TRASTUZUMAB-PKRB, BIOSIMILAR, (INTENDENCE), 10 MG Q5111 INJECTION, TRASTUZUMAB-PKRB, BIOSIMILAR, (INTENDENCE), 10 MG Q5111 INJECTION, TRASTUZUMAB-BYRR, BIOSIMILAR, (RETACRIT) (FOR NON-ESRD USE),		
INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER INFUSION TISAGENLECLEUCEL, UP TO 600 MILLION CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE SIPULEUCEL-T, MINIMUM OF 50 MILLION AUTOLOGOUS CD54+ CELLS ACTIVATED WITH PAP-GM-CSF, INCLUDING LEUKAPHERESIS AND ALL OTHER PREPARATIORY PROCEDURES, PER INFUSION RINJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, IMPORTED LIPODOX, 10 MG Q2049 INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10MG Q2050 RERXUCABTAGENE AUTOLEUCEL, UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE MARALEUCEL, UP TO 110 MILLION AUTOLOGOUS ANTI-CD19 CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE MARALEUCEL, UP TO 460 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2055 PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE AUTOLEUCEL, UP TO 100 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2056 PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE AUTOLEUCEL, UP TO 100 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2056 PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE AUTOLEUCEL, UP TO 100 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2056 PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE AUTOLEUCEL, UP TO 100 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2056 PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE AUTOLEUCEL, UP TO 100 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED ALFA, BIOSIMILAR, (REPOSITIVE AU		Q2017
AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE SIPULEUCEL-T, MINIMUM OF 50 MILLION AUTOLOGOUS CD54+ CELLS ACTIVATED WITH PAP-GM-CSF, INCLUDING LEUKAPHERESIS AND ALL OTHER PREPARATORY PROCEDURES, PER INFUSION INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, IMPORTED LIPODOX. 10 MG Q2049 BREXUCASTAGENE AUTOLEUCEL, UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE LISOCASTAGENE MARALEUCEL, UP TO 110 MILLION AUTOLOGOUS ANTI-CD19 CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE LISOCASTAGENE VICLEUCEL, UP TO 460 MILLION AUTOLOGOUS ANTI-CD19 CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE IDECASTAGENE VICLEUCEL, UP TO 460 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2055 PROCEDURES, PER THERAPEUTIC DOSE CILTACASTAGENE AUTOLEUCEL, UP TO 100 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2056 PROCEDURES, PER THERAPEUTIC DOSE CILTACASTAGENE AUTOLEUCEL, UP TO 100 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2056 PROCEDURES, PER THERAPEUTIC DOSE INJECTION, EPOSETIN ALFA, BIOSIMILAR, (RETACRIT) (FOR NON-ESRD USE), 1000 UNITS Q5106 INJECTION, PEOGRICARSTIM-JADB, BIOSIMILAR, (MVASI), 10 MG Q5107 INJECTION, PEOGRICARSTIM-JADB, BIOSIMILAR, (MVASI), 10 MG Q51101 INJECTION, PEOGRICARSTIM-JADB, BIOSIMILAR, (NEVESTYM), 1 MICROGRAM Q51101 INJECTION, TRASTUZUMAB-DASH, BIOSIMILAR, (ONTRUZANT), 10 MG Q51112 INJECTION, TRASTUZUMAB-DASH, BIOSIMILAR, (ONTRUZANT), 10 MG Q5112 INJECTION, TRASTUZUMAB-BASH, BIOSIMILAR, (ONTRUZANT), 10 MG Q5115 INJECTION, TRASTUZUMAB-BASH, BIOSIMILAR, (RETEMENCE), 10 MG Q5116 INJECTION, PEOGRICARSTIM-BAG, PEOGRIMA		Q2041
INCLUDING LEUKAPHERESIS AND ALL OTHER PREPARATORY PROCEDURES, PER INFUSION INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, IMPORTED LIPODOX, 10 MG Q2049 INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10MG Q2050 BREXUCABTAGENE AUTOLEUCEL, UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE MARALEUCEL, UP TO 110 MILLION AUTOLOGOUS ANTI-CD19 CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE VICLEUCEL, UP TO 460 MILLION AUTOLOGOUS ANTI-CD19 CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE IDECABTAGENE VICLEUCEL, UP TO 460 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE CILTACABTAGENE AUTOLEUCEL, UP TO 100 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2056 PROCEDURES, PER THERAPEUTIC DOSE INJECTION, FILGRASTIM (G-CSF), BIOSIMILAR, IMICROGRAM Q5101 INJECTION, PEOGRIN LATE, BIOSIMILAR, (RETACRIT) (FOR NON-ESRD USE), 1000 UNITS Q5106 INJECTION, BEVACIZUMAB-AWWB, BIOSIMILAR, (MVASI), 10 MG Q5107 INJECTION, PEGFILGRASTIM-CABY, BIOSIMILAR, (MVASI), 1 MICROGRAM Q5110 INJECTION, FEGFILGRASTIM-CAFI, BIOSIMILAR, (NIVESTYM), 1 MICROGRAM Q5111 INJECTION, FEGFILGRASTIM-CAFI, BIOSIMILAR, (NIVESTYM), 1 MICROGRAM Q5111 INJECTION, TRASTUZUMAB-BOTTB, BIOSIMILAR, (INDENTYAA), 10 MG Q5112 INJECTION, TRASTUZUMAB-BOTTB, BIOSIMILAR, (OGIVRI), 10 MG Q5114 INJECTION, TRASTUZUMAB-BOTTB, BIOSIMILAR, (INTEXIVANI), 10 MG Q5115 INJECTION, TRASTUZUMAB-BOTTB, BIOSIMILAR, (INTEXIVANI), 10 MG Q5116 INJECTION, TRASTUZUMAB-BOTTB, BIOSIMILAR, (INTEXIVANI), 10 MG Q5117 INJECTION, TRASTUZUMAB-BOTTB, BIOSIMILAR, (INTEXIVANI), 10 MG Q5118 INJECTION, TRASTUZUMAB-BOTTB,		Q2042
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10MG Q2050 BREXUCABTAGERE AUTOLEUCEL, UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE MARALEUCEL, UP TO 110 MILLION AUTOLOGOUS ANTI-CD19 CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE DECABTAGENE VICLEUCEL, UP TO 460 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2055 PROCEDURES, PER THERAPEUTIC DOSE CILTACABTAGENE AUTOLEUCEL, UP TO 100 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2056 PROCEDURES, PER THERAPEUTIC DOSE CILTACABTAGENE AUTOLEUCEL, UP TO 100 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2056 PROCEDURES, PER THERAPEUTIC DOSE INJECTION, FILORASTIM (G-CSF), BIOSIMILAR, (INCROGRAM Q5101 INJECTION, PEOFILICARSTIM—JOB, BIOSIMILAR, (RETACRIT) (FOR NON-ESRD USE), 1000 UNITS Q5106 INJECTION, PEGFILGRASTIM—JOB, BIOSIMILAR, (INVASI), 10 MG Q5107 INJECTION, PEGFILGRASTIM—JOB, BIOSIMILAR, (INVESTYM), 1 MICROGRAM Q5110 INJECTION, FILGRASTIM—ADE, BIOSIMILAR, (INVESTYM), 1 MICROGRAM Q5111 INJECTION, TRASTUZUMAB-PKRB, BIOSIMILAR, (INVESTYM), 10 MG Q5112 INJECTION, TRASTUZUMAB-DITB, BIOSIMILAR, (INDENTICAN), 10 MG Q5112 INJECTION, TRASTUZUMAB-DITB, BIOSIMILAR, (INTEXPAN), 10 MG Q5114 INJECTION, TRASTUZUMAB-PKRB, BIOSIMILAR, (INTEXPAN), 10 MG Q5115 INJECTION, TRASTUZUMAB-PKRB, BIOSIMILAR, (INTEXPAN), 10 MG Q5116 INJECTION, TRASTUZUMAB-PVYR, BIOSIMILAR, (INTEXPAN), 10 MG Q5117 INJECTION, PEGFILGRASTIM—ADER, BIOSIMILAR, (INTEXPAN), 10 MG Q5118 INJECTION, PEGFILGRASTIM—BMEZ, BIOSIMILAR, (INTEXPAN), 10 MG Q5119 INJECTION, PEGFILGRASTIM—BMEZ, BIOSIMILAR, (INTEXPAN), 10 MG Q5111 INJECTION, PEGFILGRA		Q2043
BREXUCABTAGENE AUTOLEUCEL, UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE MARALEUCEL, UP TO 110 MILLION AUTOLOGOUS ANTI-CD19 CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE IDECABTAGENE VICLEUCEL, UP TO 460 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2055 PROCEDURES, PER THERAPEUTIC DOSE CILTACABTAGENE AUTOLEUCEL, UP TO 100 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2056 PROCEDURES, PER THERAPEUTIC DOSE INJECTION, FILGRASTIM (G-CSF), BIOSIMILAR, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2056 INJECTION, FILGRASTIM (G-CSF), BIOSIMILAR, I MICROGRAM Q5101 INJECTION, PEOFILIN ALFA, BIOSIMILAR, RETACRITI (FOR NON-ESRD USE), 1000 UNITS Q5106 INJECTION, PEOFILIN ALFA, BIOSIMILAR, (RIVESTYM), 1 MICROGRAM Q5107 INJECTION, PEGFILGRASTIM-JMDB, BIOSIMILAR, (INVESTYM), 1 MICROGRAM Q5110 INJECTION, PEGFILGRASTIM-AGF, BIOSIMILAR, (INVESTYM), 1 MICROGRAM Q5111 INJECTION, PEGFILGRASTIM-AGF, BIOSIMILAR, (INVESTYM), 1 MICROGRAM Q5111 INJECTION, TRASTUZUMAB-DTTB, BIOSIMILAR, (INTEXTYM), 10 MG Q5112 INJECTION, TRASTUZUMAB-DTS, BIOSIMILAR, (INTEXTYM), 10 MG Q5113 INJECTION, IRRASTUZUMAB-DTS, BIOSIMILAR, (INTEXTYM), 10 MG Q5114 INJECTION, REASTIZUMAB-BORS, BIOSIMILAR, (REZUMA), 10 MG Q5116 INJECTION, REASTIZUMAB-BORS, BIOSIMILAR, (REZUMA), 10 MG Q5116 INJECTION, REASTIZUMAB-BORS, BIOSIMILAR, (REZUMA), 10 MG Q5116 INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (REZUMA), 10 MG Q5116 INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (RUXIENCE), 10 MG Q5117 INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (RUXIENCE), 10 MG Q5125 INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (RUXIENCE), 10 MG Q5125 INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (RUXIENCE), 10 MG Q5125 INJECTION, PEGFILGRASTIM-BMEZ,	INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, IMPORTED LIPODOX, 10 MG	Q2049
T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE LISOCABTAGENE MARALEUCEL, UP TO 110 MILLION AUTOLOGOUS ANTI-CD19 CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE IDECABTAGENE VICLEUCEL, UP TO 460 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2055 PROCEDURES, PER THERAPEUTIC DOSE CILTACABTAGENE AUTOLEUCEL, UP TO 100 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2056 PROCEDURES, PER THERAPEUTIC DOSE INJECTION, FILGRASTIM (G-CSF), BIOSIMILAR, INTEROGRAM Q5101 INJECTION, FPOFIIN ALFA, BIOSIMILAR, (RETACRIT) (FOR NON-ESRD USE), 1000 UNITS Q5106 INJECTION, PEOFIIN ALFA, BIOSIMILAR, (RYASI), 10 MG Q5107 INJECTION, PEGFILGRASTIM-JMDB, BIOSIMILAR, (MVASI), 10 MG Q5108 INJECTION, PEGFILGRASTIM-AAFI, BIOSIMILAR, (INVESTYM), 1 MICROGRAM Q5110 INJECTION, PEGFILGRASTIM-AAFI, BIOSIMILAR, (IDENYCA), 0.5 MG Q5111 INJECTION, TRASTUZUMAB-DTIB, BIOSIMILAR, (IDENYCA), 0.5 MG Q5112 INJECTION, TRASTUZUMAB-DTIB, BIOSIMILAR, (IDENYCA), 0.5 MG Q5113 INJECTION, TRASTUZUMAB-DTIB, BIOSIMILAR, (IDENYCA), 10 MG Q5114 INJECTION, TRASTUZUMAB-BYER, BIOSIMILAR, (IDENYCA), 10 MG Q5115 INJECTION, TRASTUZUMAB-BYER, BIOSIMILAR, (INVESTYM), 10 MG Q5116 INJECTION, TRASTUZUMAB-BYER, BIOSIMILAR, (RAMILAR, (INVESTYM), 10 MG Q5117 INJECTION, TRASTUZUMAB-BYER, BIOSIMILAR, (RAMILAR, (INVESTYM), 10 MG Q5116 INJECTION, TRASTUZUMAB-BYER, BIOSIMILAR, (RAMILAR, (INVESTYM), 10 MG Q5117 INJECTION, TRASTUZUMAB-ANNS, BIOSIMILAR, (RAMILAR, (INVESTYM), 10 MG Q5118 INJECTION, TRASTUZUMAB-BYER, BIOSIMILAR, (RAMILAR, (INVESTYM), 10 MG Q5119 INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (RAMILAR, (INVESTYM), 10 MG Q5120 INJECTION, PEGFILGRASTIM-BAPC, BIOSIMILAR, (RAMILAR, (INVESTYM), 10 MG Q5121 INJECTION, PEGFILGRASTIM-BAPC, BIOSIMILAR, (RAMILAR, (INVESTYM), 10 MG Q5122	INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10MG	Q2050
CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE IDECABTAGENE VICLEUCEL, UP TO 460 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2055 PROCEDURES, PER THERAPEUTIC DOSE CILTACABTAGENE AUTOLEUCEL, UP TO 100 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION Q2056 PROCEDURES, PER THERAPEUTIC DOSE INJECTION, FILGRASTIM (G-CSF), BIOSIMILAR, I MICROGRAM Q5101 INJECTION, EPORTIN ALFA, BIOSIMILAR, (RETACRIT) (FOR NON-ESRD USE), 1000 UNITS Q5106 INJECTION, PEOFILIR ALFA, BIOSIMILAR, (MVASI), 10 MG Q5107 INJECTION, PEGFILGRASTIM-JAMB, BIOSIMILAR, (MVASI), 10 MG Q5108 INJECTION, FILGRASTIM-AAFI, BIOSIMILAR, (INVESTYM), 1 MICROGRAM Q5110 INJECTION, PEGFILGRASTIM-BOSIMILAR, (INVESTYM), 1 MICROGRAM Q5110 INJECTION, PEGFILGRASTIM-BOSIMILAR, (INVESTYM), 1 MICROGRAM Q5110 INJECTION, PEGFILGRASTIM-BOSIMILAR, (INVESTYM), 10 MG Q5111 INJECTION, TRASTUZUMAB-DTIB, BIOSIMILAR, (INTRUZANTI), 10 MG Q5112 INJECTION, TRASTUZUMAB-PKRB, BIOSIMILAR, (INTRUZANTI), 10 MG Q5113 INJECTION, TRASTUZUMAB-PKRB, BIOSIMILAR, (IDGIVRI), 10 MG Q5114 INJECTION, TRASTUZUMAB-ABBS, BIOSIMILAR, (IDGIVRI), 10 MG Q5115 INJECTION, TRASTUZUMAB-ANS, BIOSIMILAR, (INTRUZANTI), 10 MG Q5116 INJECTION, TRASTUZUMAB-ANS, BIOSIMILAR, (TRAZIMERA), 10 MG Q5117 INJECTION, TRASTUZUMAB-ANS, BIOSIMILAR, (IRAZIMERA), 10 MG Q5117 INJECTION, TRASTUZUMAB-ANS, BIOSIMILAR, (IRAZIMERA), 10 MG Q5118 INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (RIANINTI), 10 MG Q5120 INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (RIANINTI), 10 MG Q5121 INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (RIANINTI), 10 MG Q5122 INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (RIANINTI), 10 MG Q5123 INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (RIANINTI), 10 MG Q5124 INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (RIANINTI), 10 MG Q5125 INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (RIANINTI), 10 MG Q5126 INJEC		Q2053
BCMA DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE		Q2054
(BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE INJECTION, FILGRASTIM (G-CSF), BIOSIMILAR, 1 MICROGRAM INJECTION, EPOETIN ALFA, BIOSIMILAR, (RETACRIT) (FOR NON-ESRD USE), 1000 UNITS Q5106 INJECTION, BEVACIZUMAB-AWWB, BIOSIMILAR, (MVASI), 10 MG Q5107 INJECTION, PEGFILGRASTIM-JMDB, BIOSIMILAR, (FULPHILA), 0.5 MG INJECTION, FILGRASTIM-AAFI, BIOSIMILAR, (INVESTYM), 1 MICROGRAM Q5108 INJECTION, PEGFILGRASTIM-DBQV, BIOSIMILAR, (INVESTYM), 1 MICROGRAM Q5110 INJECTION, PEGFILGRASTIM-BIOSIMILAR, (INDENYCA), 0.5 MG Q5111 INJECTION, TRASTUZUMAB-DTB, BIOSIMILAR, (IDENYCA), 0.5 MG Q5112 INJECTION, TRASTUZUMAB-PKRB, BIOSIMILAR, (OGIVRI), 10 MG Q5113 INJECTION, TRASTUZUMAB-DRST, BIOSIMILAR, (OGIVRI), 10 MG Q5114 INJECTION, TRASTUZUMAB-ABBS, BIOSIMILAR, (TRAZIMERA), 10 MG Q5115 INJECTION, TRASTUZUMAB-ANNS, BIOSIMILAR, (TRAZIMERA), 10 MG Q5116 INJECTION, TRASTUZUMAB-ANNS, BIOSIMILAR, (KRAJINTI), 10 MG Q5117 INJECTION, BEVACIZUMAB-BVZR, BIOSIMILAR, (RENZIMERA), 10 MG Q5117 INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (RIABEV), 10 MG Q5119 INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (RIASTENZO), 0.5 MG Q5120 INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (RIASTIN), 10 MG Q5121 INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (RIASHI), 10 MG Q5122 INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (RIASHI), 10 MG Q5123 INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (RIASHI), 10 MG Q5124 INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (RIASHI), 10 MG Q5125 INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (RIASHI), 10 MG Q5126 INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (RIASHI), 10 MG Q5127 INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (RIASHI), 10 MG Q5128 INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (RIASHI), 10 MG Q5129 INJECTION, DEVACIZUMAD-ACCI (Vegzelma), biosimilar, 0.5 mg Q5120 INJECTION, PEGFILGRASTIM-DOSK (fylnetra), biosimilar, 0.5 mg Q5127 Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg	(BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION	Q2055
INJECTION, FILGRASTIM (G-CSF), BIOSIMILAR, 1 MICROGRAM INJECTION, EPOETIN ALFA, BIOSIMILAR, (RETACRIT) (FOR NON-ESRD USE), 1000 UNITS Q5106 INJECTION, BEVACIZUMAB-AWWB, BIOSIMILAR, (MVASI), 10 MG INJECTION, PEGFILGRASTIM-JMDB, BIOSIMILAR, (FULPHILA), 0.5 MG INJECTION, FILGRASTIM-AAFI, BIOSIMILAR, (FULPHILA), 0.5 MG INJECTION, FILGRASTIM-AAFI, BIOSIMILAR, (FULPHILA), 0.5 MG INJECTION, PEGFILGRASTIM-CBQV, BIOSIMILAR, (INDENYCA), 0.5 MG Q5110 INJECTION, TRASTUZUMAB-DTTB, BIOSIMILAR, (UDENYCA), 0.5 MG Q5111 INJECTION, TRASTUZUMAB-PKRB, BIOSIMILAR, (INTRUZANT), 10 MG Q5112 INJECTION, TRASTUZUMAB-DKST, BIOSIMILAR, (OGIVRI), 10 MG Q5113 INJECTION, RITUXIMAB-ABBS, BIOSIMILAR, (OGIVRI), 10 MG Q5116 INJECTION, TRASTUZUMAB-ORYP, BIOSIMILAR, (TRAZIMERA), 10 MG Q5117 INJECTION, REVACIZUMAB-BVZR, BIOSIMILAR, (TRAZIMERA), 10 MG Q5118 INJECTION, RITUXIMAB-ANNS, BIOSIMILAR, (ZIRABEV), 10 MG Q5118 INJECTION, RITUXIMAB-PVVR, BIOSIMILAR, (RUXIENCE), 10 MG Q5119 INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (RUXIENCE), 10 MG Q5120 INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (RIVYEPRIA), 0.5 MG Q5122 INJECTION, FILGRASTIM-APGF, BIOSIMILAR, (RIABNI), 10 MG Q5123 INJECTION, FILGRASTIM-APOW, BIOSIMILAR, (RIABNI), 10 MG Q5125 Injection, Devacizumab-adcd (vegzelma), biosimilar, 0.5 mg Q5126 Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg Q5127 Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg	(BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION	Q2056
INJECTION, BEVACIZUMAB-AWWB, BIOSIMILAR, (MVASI), 10 MG INJECTION, PEGFILGRASTIM-JMDB, BIOSIMILAR, (FULPHILA), 0.5 MG INJECTION, FILGRASTIM-AAFI, BIOSIMILAR, (NIVESTYM), 1 MICROGRAM INJECTION, PEGFILGRASTIM-CBQV, BIOSIMILAR, (UDENYCA), 0.5 MG INJECTION, TRASTUZUMAB-DTIB, BIOSIMILAR, (ONTRUZANT), 10 MG INJECTION, TRASTUZUMAB-PKRB, BIOSIMILAR, (HERZUMA), 10 MG INJECTION, TRASTUZUMAB-PKRB, BIOSIMILAR, (OGIVRI), 10 MG INJECTION, RITUXIMAB-ABBS, BIOSIMILAR, (OGIVRI), 10 MG INJECTION, TRASTUZUMAB-QYYP, BIOSIMILAR, (TRAZIMERA), 10 MG INJECTION, TRASTUZUMAB-ANNS, BIOSIMILAR, (TRAZIMERA), 10 MG INJECTION, TRASTUZUMAB-ANNS, BIOSIMILAR, (KANJINTI), 10 MG INJECTION, BEVACIZUMAB-BVZR, BIOSIMILAR, (ZIRABEV), 10 MG INJECTION, RITUXIMAB-PVVR, BIOSIMILAR, (RUXIENCE), 10 MG INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (ZIEXTENZO), 0.5 MG INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (RYEXTENZO), 0.5 MG INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (RIABNI), 10 MG INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG INJECTION, PEGFILGRASTIM-APOW, BIOSIMILAR, (RIABNI), 10 MG INJECTION, PEGFILGRASTIM-APOW, BIOSIMILAR, (RIABNI), 10 MG INJECTION, PEGFILGRASTIM-TOM,	INJECTION, FILGRASTIM (G-CSF), BIOSIMILAR, 1 MICROGRAM	Q5101
INJECTION, BEVACIZUMAB-AWWB, BIOSIMILAR, (MVASI), 10 MG INJECTION, PEGFILGRASTIM-JMDB, BIOSIMILAR, (FULPHILA), 0.5 MG INJECTION, FILGRASTIM-AAFI, BIOSIMILAR, (NIVESTYM), 1 MICROGRAM INJECTION, PEGFILGRASTIM-CBQV, BIOSIMILAR, (UDENYCA), 0.5 MG INJECTION, TRASTUZUMAB-DTIB, BIOSIMILAR, (ONTRUZANT), 10 MG INJECTION, TRASTUZUMAB-PKRB, BIOSIMILAR, (HERZUMA), 10 MG INJECTION, TRASTUZUMAB-PKRB, BIOSIMILAR, (HERZUMA), 10 MG INJECTION, RITUXIMAB-ABBS, BIOSIMILAR, (OGIVRI), 10 MG INJECTION, TRASTUZUMAB-QYYP, BIOSIMILAR, (TRAZIMERA), 10 MG INJECTION, TRASTUZUMAB-ANNS, BIOSIMILAR, (TRAZIMERA), 10 MG INJECTION, TRASTUZUMAB-ANNS, BIOSIMILAR, (KANJINTI), 10 MG INJECTION, BEVACIZUMAB-BVZR, BIOSIMILAR, (KANJINTI), 10 MG INJECTION, RITUXIMAB-PVVR, BIOSIMILAR, (RUXIENCE), 10 MG INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (RIXETENZO), 0.5 MG INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (RIXETENZO), 0.5 MG INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (RIXETENZO), 0.5 MG INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (RIABNI), 10 MG INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG INJECTION, PEGFILGRASTIM-APGM, BIOSIMILAR, (RIABNI), 10 MG INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG INJECTION, PEGFILGRASTIM-APGM, BIOSIMILAR, (RIABNI), 10 MG INJECTION, PILGRASTIM-APOW, BIOSIMILAR, (RIABNI), 10 MG INJECTION, PEGFILGRASTIM-APOW, BIOSIMILAR, (RIABNI), 10 MG INJECTION, PEGFILGRASTIM-FORK (RELEUKO), 1 MICROGRAM Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg	INJECTION, EPOETIN ALFA, BIOSIMILAR, (RETACRIT) (FOR NON-ESRD USE), 1000 UNITS	Q5106
INJECTION, FILGRASTIM-AAFI, BIOSIMILAR, (NIVESTYM), 1 MICROGRAM INJECTION, PEGFILGRASTIM-CBQV, BIOSIMILAR, (UDENYCA), 0.5 MG Q5111 INJECTION, TRASTUZUMAB-DTTB, BIOSIMILAR, (ONTRUZANT), 10 MG Q5112 INJECTION, TRASTUZUMAB-PKRB, BIOSIMILAR, (HERZUMA), 10 MG Q5113 INJECTION, TRASTUZUMAB-DKST, BIOSIMILAR, (OGIVRI), 10 MG Q5114 INJECTION, RITUXIMAB-ABBS, BIOSIMILAR, 10 MG Q5115 INJECTION, TRASTUZUMAB-QYYP, BIOSIMILAR, (TRAZIMERA), 10 MG Q5116 INJECTION, TRASTUZUMAB-ANNS, BIOSIMILAR, (KANJINTI), 10 MG Q5117 INJECTION, BEVACIZUMAB-BVZR, BIOSIMILAR, (ZIRABEV), 10 MG Q5118 INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (ZIEXTENZO), 0.5 MG INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (RIABNI), 10 MG Q5120 INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG Q5121 INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG Q5122 INJECTION, FILGRASTIM-AYOW, BIOSIMILAR, (RELEUKO), 1 MICROGRAM Q5125 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg Q5126 Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg Q5127 Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg Q5130		Q5107
INJECTION, PEGFILGRASTIM-CBQV, BIOSIMILAR, (UDENYCA), 0.5 MG INJECTION, TRASTUZUMAB-DITB, BIOSIMILAR, (ONTRUZANT), 10 MG INJECTION, TRASTUZUMAB-PKRB, BIOSIMILAR, (HERZUMA), 10 MG INJECTION, TRASTUZUMAB-DKST, BIOSIMILAR, (OGIVRI), 10 MG INJECTION, RITUXIMAB-ABBS, BIOSIMILAR, 10 MG INJECTION, RITUXIMAB-ABBS, BIOSIMILAR, 10 MG INJECTION, TRASTUZUMAB-QYYP, BIOSIMILAR, (TRAZIMERA), 10 MG INJECTION, TRASTUZUMAB-ANNS, BIOSIMILAR, (KANJINTI), 10 MG INJECTION, BEVACIZUMAB-BVZR, BIOSIMILAR, (ZIRABEV), 10 MG INJECTION, RITUXIMAB-PVVR, BIOSIMILAR, (ZIRABEV), 10 MG INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (RUXIENCE), 10 MG INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (ZIEXTENZO), 0.5 MG INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (NYVEPRIA), 0.5 MG INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG INJECTION, FILUXIMAB-ARRX, BIOSIMILAR, (RELEUKO), 1 MICROGRAM INJECTION, Devacizumab-maly, biosimilar, (alymsys), 10 mg Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg	INJECTION, PEGFILGRASTIM-JMDB, BIOSIMILAR, (FULPHILA), 0.5 MG	Q5108
INJECTION, TRASTUZUMAB-DTTB, BIOSIMILAR, (ONTRUZANT), 10 MG INJECTION, TRASTUZUMAB-PKRB, BIOSIMILAR, (HERZUMA), 10 MG INJECTION, TRASTUZUMAB-DKST, BIOSIMILAR, (OGIVRI), 10 MG INJECTION, RITUXIMAB-ABBS, BIOSIMILAR, 10 MG INJECTION, TRASTUZUMAB-QYYP, BIOSIMILAR, (TRAZIMERA), 10 MG INJECTION, TRASTUZUMAB-QYYP, BIOSIMILAR, (TRAZIMERA), 10 MG INJECTION, TRASTUZUMAB-ANNS, BIOSIMILAR, (KANJINTI), 10 MG INJECTION, BEVACIZUMAB-BVZR, BIOSIMILAR, (ZIRABEV), 10 MG INJECTION, RITUXIMAB-PVVR, BIOSIMILAR, (RUXIENCE), 10 MG INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (ZIEXTENZO), 0.5 MG INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (NYVEPRIA), 0.5 MG INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG INJECTION, FILGRASTIM-AYOW, BIOSIMILAR, (RELEUKO), 1 MICROGRAM INJECTION, FILGRASTIM-AYOW, BIOSIMILAR, (RELEUKO), 1 MICROGRAM INJECTION, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg INJECTION, bevacizumab-adcd (vegzelma), biosimilar, 10 mg INJECTION, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg	INJECTION, FILGRASTIM-AAFI, BIOSIMILAR, (NIVESTYM), 1 MICROGRAM	Q5110
INJECTION, TRASTUZUMAB-PKRB, BIOSIMILAR, (HERZUMA), 10 MG INJECTION, TRASTUZUMAB-DKST, BIOSIMILAR, (OGIVRI), 10 MG INJECTION, RITUXIMAB-ABBS, BIOSIMILAR, 10 MG INJECTION, TRASTUZUMAB-QYYP, BIOSIMILAR, (TRAZIMERA), 10 MG INJECTION, TRASTUZUMAB-ANNS, BIOSIMILAR, (TRAZIMERA), 10 MG INJECTION, TRASTUZUMAB-ANNS, BIOSIMILAR, (KANJINTI), 10 MG INJECTION, BEVACIZUMAB-BVZR, BIOSIMILAR, (ZIRABEV), 10 MG INJECTION, RITUXIMAB-PVVR, BIOSIMILAR, (RUXIENCE), 10 MG INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (RIZIEXTENZO), 0.5 MG INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (NYVEPRIA), 0.5 MG INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG INJECTION, FILGRASTIM-AYOW, BIOSIMILAR, (RELEUKO), 1 MICROGRAM INJECTION, PEGFILGRASTIM-AYOW, BIOSIMILAR, (RELEUKO), 1 MICROGRAM INJECTION, FILGRASTIM-AYOW, BIOSIMILAR, (RELEUKO), 1 MICROGRAM INJECTION, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg INJECTION, bevacizumab-adcd (vegzelma), biosimilar, 10 mg INJECTION, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg	INJECTION, PEGFILGRASTIM-CBQV, BIOSIMILAR, (UDENYCA), 0.5 MG	Q5111
INJECTION, TRASTUZUMAB-DKST, BIOSIMILAR, (OGIVRI), 10 MG INJECTION, RITUXIMAB-ABBS, BIOSIMILAR, 10 MG INJECTION, TRASTUZUMAB-QYYP, BIOSIMILAR, (TRAZIMERA), 10 MG INJECTION, TRASTUZUMAB-ANNS, BIOSIMILAR, (KANJINTI), 10 MG INJECTION, BEVACIZUMAB-BVZR, BIOSIMILAR, (ZIRABEV), 10 MG INJECTION, RITUXIMAB-PVVR, BIOSIMILAR, (RUXIENCE), 10 MG INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (ZIEXTENZO), 0.5 MG INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (NYVEPRIA), 0.5 MG INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG Q5122 INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG Q5123 INJECTION, FILGRASTIM-AYOW, BIOSIMILAR, (RELEUKO), 1 MICROGRAM Q5125 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg Q5126 Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg Q5129 Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg Q5130		Q5112
INJECTION, RITUXIMAB-ABBS, BIOSIMILAR, 10 MG INJECTION, TRASTUZUMAB-QYYP, BIOSIMILAR, (TRAZIMERA), 10 MG INJECTION, TRASTUZUMAB-ANNS, BIOSIMILAR, (KANJINTI), 10 MG INJECTION, BEVACIZUMAB-BVZR, BIOSIMILAR, (ZIRABEV), 10 MG INJECTION, RITUXIMAB-PVVR, BIOSIMILAR, (RUXIENCE), 10 MG INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (ZIEXTENZO), 0.5 MG INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (NYVEPRIA), 0.5 MG INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG INJECTION, FILGRASTIM-AYOW, BIOSIMILAR, (RELEUKO), 1 MICROGRAM Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg Q5126 Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg Q5130		
INJECTION, TRASTUZUMAB-QYYP, BIOSIMILAR, (TRAZIMERA), 10 MG INJECTION, TRASTUZUMAB-ANNS, BIOSIMILAR, (KANJINTI), 10 MG INJECTION, BEVACIZUMAB-BVZR, BIOSIMILAR, (ZIRABEV), 10 MG INJECTION, RITUXIMAB-PVVR, BIOSIMILAR, (RUXIENCE), 10 MG INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (ZIEXTENZO), 0.5 MG INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (NYVEPRIA), 0.5 MG INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG INJECTION, FILGRASTIM-AYOW, BIOSIMILAR, (RELEUKO), 1 MICROGRAM Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg Q5126 Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg Q5129 Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg		
INJECTION, TRASTUZUMAB-ANNS, BIOSIMILAR, (KANJINTI), 10 MG INJECTION, BEVACIZUMAB-BVZR, BIOSIMILAR, (ZIRABEV), 10 MG INJECTION, RITUXIMAB-PVVR, BIOSIMILAR, (RUXIENCE), 10 MG INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (ZIEXTENZO), 0.5 MG INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (RIVYPERIA), 0.5 MG INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG INJECTION, FILGRASTIM-AYOW, BIOSIMILAR, (RELEUKO), 1 MICROGRAM Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg		
INJECTION, BEVACIZUMAB-BVZR, BIOSIMILAR, (ZIRABEV), 10 MG INJECTION, RITUXIMAB-PVVR, BIOSIMILAR, (RUXIENCE), 10 MG INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (ZIEXTENZO), 0.5 MG INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (RIVYPERIA), 0.5 MG INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG INJECTION, FILGRASTIM-AYOW, BIOSIMILAR, (RELEUKO), 1 MICROGRAM INJECTION, PEGFILGRASTIM-AYOW, BIOSIMILAR, (RIABNI), 10 MG Q5123 INJECTION, FILGRASTIM-AYOW, BIOSIMILAR, (RELEUKO), 1 MICROGRAM Q5125 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg Q5126 Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg Q5127 Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg Q5130		
INJECTION, RITUXIMAB-PVVR, BIOSIMILAR, (RUXIENCE), 10 MG INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (ZIEXTENZO), 0.5 MG INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (NYVEPRIA), 0.5 MG INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG INJECTION, FILGRASTIM-AYOW, BIOSIMILAR, (RELEUKO), 1 MICROGRAM Q5125 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg Q5126 Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg Q5127 Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg Q5130	· '	
INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (ZIEXTENZO), 0.5 MG INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (NYVEPRIA), 0.5 MG INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG INJECTION, FILGRASTIM-AYOW, BIOSIMILAR, (RELEUKO), 1 MICROGRAM Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg Q5126 Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg Q5127 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg Q5129 Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg Q5130		
INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (NYVEPRIA), 0.5 MG INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG INJECTION, FILGRASTIM-AYOW, BIOSIMILAR, (RELEUKO), 1 MICROGRAM Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg Q5126 Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg Q5127 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg Q5129 Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg Q5130		
INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG INJECTION, FILGRASTIM-AYOW, BIOSIMILAR, (RELEUKO), 1 MICROGRAM Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg Q5126 Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg Q5127 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg Q5129 Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg Q5130		
INJECTION, FILGRASTIM-AYOW, BIOSIMILAR, (RELEUKO), 1 MICROGRAM Q5125 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg Q5126 Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg Q5127 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg Q5129 Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg Q5130		
Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mgQ5126Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mgQ5127Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mgQ5129Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mgQ5130		
Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mgQ5127Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mgQ5129Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mgQ5130		
Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg Q5129 Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg Q5130	Injection, heyacizumah-maly, hiosimilar (alymsys), 10 ma	Q5126
Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg Q5130		
	Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg	
LOMUSTINE, ORAL, 10MG S0178	Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg	Q5129
	Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg	Q5129 Q5130